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ABSTRACT 
 
Duchenne muscular dystrophy (DMD) is the most common inherited pediatric muscle 
dystrophy. It is characterized by muscle degeneration, resulting in fibrosis that is a significant 
impediment to both endogenous muscle repair and any potential regenerative strategy. At 
present, there are few therapies that specifically address fibrosis and microenvironment 
improvement, but one possibility rests in targeting the Wilms’ tumour 1 (Wt1) protein. Wt1 is a 
zinc finger transcription factor, recently shown to be expressed in fibrotic conditions such as 
Dupuytren’s disease and pulmonary fibrosis. This thesis examines the expression pattern of Wt1 
in several mouse models of DMD, through both histological quantification of Wt1 protein, and 
quantification of Wt1 isoform mRNA. Additionally, fibrosis is quantified through Masson’s 
trichrome staining of collagen. An increased proportion of Wt1 immunoreactive nuclei was 
found in the diaphragm and gastrocnemius of DMD disease models prior to and during early 
fibrosis, but returned to basal levels during late fibrosis. These results suggest that nuclear Wt1 
immunoreactivity may precede college deposition, and that it should be investigated further in 
the future.  
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SUMMARY FOR LAY AUDIENCE 
 
Duchenne muscular dystrophy (DMD) is a severe muscle disorder affecting children. 
DMD has no cure, and most patients with the disease are expected to only live to their mid-
twenties. The most recognizable symptoms of DMD are muscle weakness and muscle loss. 
DMD is a genetic condition, caused by a mutation in the gene that normally produces dystrophin 
protein. Genes make proteins by first making RNA, which can then be read by cells to assemble 
the protein. Dystrophin is an important protein for maintaining the structure of muscle cells. 
Mutations in the gene which produces dystrophin can make the dystrophin it produces not 
function properly. When the function of dystrophin is reduced, muscle cells become more likely 
to die. Over time, this increased muscle cell death causes scarring inside of muscles, preventing 
muscles from functioning properly. This scarring acts as a barrier, preventing both normal 
muscle repair and treatments to increase muscle function. Presently, there are few treatments that 
specifically target this scarring, but one possibility rests in targeting the Wilms Tumor 1 (Wt1) 
protein. Wt1 is a protein which can alter the production of other proteins. It was originally found 
in cancer, but it has recently been shown to be expressed in some diseases where scarring occurs, 
such as Dupuytren’s disease. This indicates its production might occur when scarring occurs. 
This thesis examines the patterns of Wt1 production in several mouse models of DMD. This is 
done by, in these models, staining Wt1 protein and looking at it under a microscope, and also 
examining how much RNA of Wt1 is made. Additionally, scarring is examined by staining the 
scar tissue and examining it under a microscope. The percent of cell nuclei which had Wt1 inside 
of them was found to be increased prior to, and during, scarring, but decreased back down to 
normal levels after scarring had taken place. These results suggest that an increased presence of 
Wt1 in the nucleus may take place before scarring, and that it should be investigated further. 
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1 LITERATURE REVIEW 
 
1.1 Duchenne Muscular Dystrophy (DMD) 
1.1.1 Overview 
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder and the 
most common inherited pediatric muscle dystrophy. It is characterized by muscle wasting and 
muscle weakness, which worsens throughout development. Initial presentation in children takes 
place at three to five years of age1–3. DMD follows an X-linked recessive pattern of inheritance, 
producing pathology at a far higher rate in males rather than females. It arises due to spontaneous 
or inherited mutations in the dystrophin gene4. In most cases, the muscle degeneration present in 
DMD ultimately results in cardiac and respiratory complications that reduce life expectancy to 
the mid-twenties5–8 .  
1.1.2 Clinical Features 
In DMD patients, muscle degeneration is most severe in skeletal and cardiac muscle. 
Newborns exhibit no symptoms of pathology, but slowly become more affected over time, 
occasionally with mild delays in gross motor development as early as age two2,3. Weakness 
begins centrally in the proximal lower limbs and trunk, and progresses to eventually include the 
upper limbs and distal muscles9–11. Calf hypertrophy, waddling gait, and increased lumbar 
lordosis become more common by six years of age. Gowers’ sign may also become visible at this 
time2,3,11. This disorder often culminates in orthopedic complications, such as scoliosis, and 
frequent joint contractures in the lower limbs11–13. By the onset of puberty, both extensive 
postural distortion and substantial loss of motor function have taken place, forcing use of 
orthopedic aids to maintain mobility2,11.  
2 
 
 
 
As muscles throughout the body weaken, the heart and lungs begin to fail7. Loss of 
musculature needed for respiration produces several secondary conditions, such as obstructive 
sleep apnea and hypoventilation14. Pulmonary infection affecting the respiratory tract can further 
complicate this. Heart failure can occasionally remain masked until late into the disease course 
due to inactivity2. Early pre-clinical cardiac involvement is present in 25% of patients under six 
years of age. This transitions into full cardiac involvement over time, affecting all patients over 
eighteen years of age15.  
Females which possess only a single mutant allele often have a much milder form of 
DMD, and act as carriers for the condition. Generally, symptoms in females are limited to mild 
muscle weakness, and elevated creatine kinase (CK) levels, with a small chance of cardiac 
involvement16,17. 
1.1.3 Diagnosis 
Diagnosis of DMD involves several strategies. Serum CK levels are often used as an 
initial criterion, and are usually ten or twenty fold the norm in children with the condition2,11,18. 
Genetic testing is the standard method to confirm a diagnosis of DMD, though it still struggles 
with cost and availability issues, and does not account for other factors influencing dystrophin 
function or expression2,19,20. In the case that genetic testing is not conclusive, muscle biopsy must 
be utilized. Immunostaining21 and western blot analysis22 can be used to evaluate dystrophin 
size, expression level, and expression location. Unfortunately, this technique also has marked 
downsides2,7,11,22. DMD patients already experience reduced ability to replenish dying muscle 
tissue, and the process of the biopsy may exacerbate issues associated with this.  
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1.1.4 Pathology 
The pathology in DMD results from minimal dystrophin function, or decreased synthesis 
of functional dystrophin23–25. The gene coding for dystrophin is over 2000 kb in length, and is the 
largest in the human body. It is expressed as early as nine weeks during human fetal 
development26. Dystrophin has multiple isoforms, and is expressed in various organ systems. 
Some isoforms are expressed near-ubiquitously, while others are restricted to particular organ 
systems. Nonetheless, the major burden of the DMD pathology is linked to muscle decline, and 
dystrophin’s function therein27. The most common mutations which produce cases of DMD are 
deletions of one or more exons, usually those which cause disruption of the reading frame. This 
produces dystrophin transcripts which are vulnerable to nonsense mediated decay28–31. This 
contrasts with Becker’s muscular dystrophy (BMD), another condition produced by mutations in 
the dystrophin gene, where in-frame mutations are the cause of the condition. This results in 
production of still partially functional dystrophin. Individuals with BMD usually experience 
milder symptoms, and may live 50-60 years before serious complications develop23,31,32.  
Normally, dystrophin expressed in muscle cells localizes to the cytoplasmic face of the 
sarcolemma, where it can form the dystrophin-associated protein complex33 (Fig. 1). This 
complex spans the sarcolemma, and its components can be divided into three categories of 
protein dependent on their location. In the intracellular compartment, neuronal nitric oxide 
synthase (nNOS), dystrobrevin, syntrophins, and dystrophin can be found. Dystrobrevin and the 
syntrophins mediate binding of nNOS to dystrophin, and dystrophin itself acts as the key protein 
connecting these intracellular proteins to the other components of the dystrophin-associated 
protein complex. The transmembrane proteins forming part of this complex are β-dystroglycan, 
sarcoglycans and sarcospan. β-dystroglycan links these proteins to dystrophin, and to the 
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extracellular components of the dystrophin-associated protein complex31,34. Sarcoglycans and 
sarcospan play additional roles in stabilizing the complex through interactions with dystrobrevin, 
and securing the complex to the sarcolemma35,36.  
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Figure 1. Dystrophin-associated protein complex 
Dystrophin’s amino-terminus interacts with the actin cytoskeleton, while its carboxyl-terminus 
forms the dystrophin-associated protein complex alongside several other proteins, including 
dystroglycans and sarcoglycans. This complex can then interact with the extracellular matrix, 
through mediators such as laminin. This provides integrity to the muscle cell sarcolemma. This 
complex, additionally, allows localization of other proteins to the plasma membrane, such as 
neuronal nitroc oxide synthase (nNOS).  
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The major extracellular component is α-dystroglycan, which binds to β-dystroglycan, and 
enables the connection of the complex to components of the extracellular matrix, such as 
laminin34. Few mutations in dystroglycans are identified, though this appears to be as a result of 
these mutations being embryonically lethal, as opposed to any protective mechanism33,37,38. 
Dystrophin itself mediates the connection of these components to microtubules and the actin 
cytoskeleton. Its absence can lead to a disorganization of the microtubule network31,39,40. The 
dystrophin-associated protein complex interacts with several other proteins to form rib-like 
lattices around the cell, termed costameres41,42. These structures distribute contractile forces 
laterally throughout the sarcolemma to the basal lamina43. The dystrophin-associated protein 
complex additionally enables transduction of mechanical signals between the intracellular and 
extracellular environments44. The absence of dystrophin increases the permeability of muscle 
cells, as confirmed by dye incorporation rates45,46. 
There are several theories linking dystrophin loss to the dystrophic phenotype present in 
DMD. The first, and most widely accepted theory, is that with the loss of the dystrophin-
associated protein complex, cells lose the ability to cope with mechanical stress. During 
contraction, the sarcolemma tears, allowing accumulation of extracellular protein inside the 
muscle cell, ultimately triggering cell death42,45,47. In X chromosome-linked muscular dystrophy 
(Mdx) mice, a dystrophin knockout model which experiences muscle degeneration and thus a 
higher proportion of centrally-nucleated myofibers, immobilization has been shown to reduce the 
proportion of centrally-nucleated myofibres48. Beyond the mechanical implications of dystrophin 
loss, other cell functions also become dysregulated, indirectly bringing about cell death. 
Stretching of the sarcolemma inappropriately opens calcium channels, and compounded with 
Ca2+ influx through microlesions, it becomes impossible to maintain cytosolic Ca2+ 
7 
 
 
 
concentration. Consistent high Ca2+ levels prompt a positive feedback loop, as calpain proteases 
become active and cleave proteins in the plasma membrane, eventually causing apoptosis45,49. 
Neuronal nitric oxide synthase (nNOS) is normally sequestered to the sarcolemma by 
dystrophin-associated proteins. It is delocalized into the cytoplasm in cases of DMD50. This 
impedes adequate vasodilation, reducing the ability for muscle to regulate oxygen exchange, and 
can thus cause muscle ischemia. However, studies using nNOS knockout mice show different 
phenotypes than those observed in dystrophin knockout mice, suggesting that the loss of nNOS 
localization regulation does not alone account for the pathophysiology of DMD45,51,52. 
Nonetheless, experimental models have shown that boosting NO signaling may ameliorate some 
of the skeletal muscle pathology in DMD53. A portion of muscle cell mechanotransduction is lost 
when the dystrophin-associated protein complex fails to form, leading to dysregulation of 
multiple genes. Unfortunately, little research has so far been conducted on this topic, and there is 
a poor understanding in the literature of how this interacts with DMD pathology44,45. It is likely a 
combination of these pathways which results in the DMD dystrophic phenotype. As muscle cells 
die, the tissue becomes chronically inflamed, and is remodeled into fatty and fibrous connective 
tissue through fibrosis47.  
1.1.5 Initiation of Fibrosis in DMD 
Fibrosis is a pathological deposition of extracellular matrix, resulting in damage to the 
architecture of the tissue in which the fibrosis is occurring. Tissue injury is the initial cause of 
fibrosis54,55. This can be through external means, such as chemical or physical insult, or 
internally, such as in the case of genetic conditions. Some extracellular matrix deposition occurs 
normally in the process of tissue repair, but when this lasts too long, or is too severe, clearance 
becomes difficult, and permanent scarring takes place54,55. Conditions where fibrosis is a major 
8 
 
 
 
component of pathology affect a wide range of organ systems: chronic renal disease56, fibrotic 
pulmonary diseases57, alcoholic liver disease58, and DMD59, are all examples. Estimates place the 
number of United States (US) adults with chronic renal disease alone at several million cases60. 
DMD itself makes up a comparatively smaller proportion of fibrotic conditions in the US, but the 
disease course and outcomes are much more severe, with muscle loss and ensuing fibrosis 
causing death. For some fibrotic conditions, addressing the underlying causes of fibrosis 
initiation may be difficult or impossible. It is therefore pertinent that research is conducted on 
methods to predict, halt, and even reverse fibrosis, in order to reduce disease burden in the 
future.  
The fibrogenic response, in broad terms, consists of four phases. The first phase is 
initiation, where the structure to become fibrotic is injured. In the case of DMD, this is through 
the uncontrolled death of muscle cells. This triggers release of inflammatory mediators such as 
cytokines and chemokines, recruiting inflammatory cells55,61. There are several types of 
inflammatory cells, but some of the most common are lymphocytes and macrophages55,62. The 
macrophage population at the site of damaged muscle is heterogenous, with some portion being 
M1 and another portion being M263,64. Once they arrive at the site of cell death, macrophages and 
lymphocytes can induce the second and third phases of fibrosis. These are, respectively, effector 
cell activation, and extracellular matrix production55. The activated effector cells can engage in 
signaling feedback with the inflammatory cell population, potentially modifying their behavior 
further65–67. The initial M1 macrophage population can furthermore prompt myogenic precursor 
cell growth68. Some of the key effector cell types are fibroblasts and myofibroblasts, which both 
synthesize extracellular matrix proteins69. This new matrix consists primarily of type I and III 
collagen, basement-membrane proteins, and fibronectins55,70, but also has several other elements, 
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such as proteoglycans, and fibrinogen71–73. Myofibroblasts also function to contract this matrix 
and surrounding tissue structure together55,63. There are numerous pathways used by 
inflammatory cells in this process, such as the transforming growth factor beta (TGF-β) pathway. 
TGF-β is not only secreted by inflammatory cells, but is also secreted by effector cells to sustain 
the fibrogenic response once it is active55,62. TGF-β may act through a canonical pathway in 
which its binding to one of the TGF-β receptors mediates SMAD signaling, or through non-
canonical mitogen-activated protein kinases (MAPKs) and c-abl pathways that upregulate the 
transcription of other fibrotic signals73–75. Under normal circumstances, these effects can be 
beneficial, allowing repair of damaged structures55,63,69. The initial matrix scaffold set down in 
the inflammatory response is gradually replaced by new cells. The M1 macrophages give way to 
their M2 counterparts. In muscle, they prompt differentiation of myogenic precursor cells into 
myofibers, and the tissue is repaired63,68. In chronically inflamed tissue, this process is 
unbalanced. There can be persistence of the M1 macrophage population, or an unbalanced 
activation of M2 macrophage population subsets. This leads into the fourth phase of the 
fibrogenic response, where there is excessive deposition and insufficient resorption of 
extracellular matrix, ultimately resulting in pathogenesis55,63.  
The fibrosis experienced in DMD is profound. It is one of the major pathological factors 
of DMD that brings about ultimate muscle dysfunction. Newly regenerated muscle tissue in 
DMD patients is vulnerable to cell death, creating a cyclical state of degeneration. This produces 
chronic inflammation characterized by incomplete muscle regeneration, and an absence of 
extracellular matrix remodeling. Over time, muscle tissue is increasingly replaced by 
extracellular matrix, further reducing the muscle strength, and making it prone to increased 
damage in the future. The ability of satellite cells to repair the tissue deteriorates over time, 
10 
 
 
 
though there is some uncertainty whether this is either due to an inability to replicate, or an 
inability to produce additional functional muscle tissue63,76,77. There has been a long-standing 
body of evidence which suggests that, even before the onset of muscle loss, there is an increase 
in collagen deposition in the endomysium78–81. A 2009 study evaluated several histological 
features in DMD patients, including fibrosis, fatty degeneration, myofiber size, and 
necro/basophilic fibers, and compared these to several motor outcomes. These outcomes 
included quadriceps strength, ages at loss of walking and wheelchair confinement, scoliosis, and 
manual muscle testing. Of all the parameters assessed, only fibrosis in the endomysium 
correlated with poorer motor outcome. This was possibly mediated through fibrosis-induced 
separation of the muscle tissue from associated vessels. Layers of extracellular matrix would 
reduce the efficiency of oxygen diffusion to muscle, possibly causing ischemia of the muscle80. 
1.1.6 The Fibrotic Microenvironment in DMD 
The normal muscle microenvironment is compromised in fibrosis, taking on 
characteristics which promote further fibrosis, rather than healing. There are shifts not only in the 
cell populations which compose the tissue, but also in the formulation of the extracellular matrix 
which is produced. In terms of cell types, the fibrotic microenvironment leads to changes in cells 
responsible for regeneration, for inflammation, and for production of extracellular matrix. There 
is evidence that the myoblast population’s ability to replenish cells, and differentiation 
capability, may be altered in the fibrotic microenvironment. Although many mediators of this 
event have been identified, one major candidate has been TGF-β73. TGF-β has been shown to 
block myoblast differentiation82, trigger its apoptosis83 or myofibroblast transdifferentiation84, 
and promote myostatin expression in myoblasts85. Hypoxia has also been implicated as a 
possible factor influencing the ability of myoblasts and muscle satellite cells to differentiate and 
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proliferate, though there is disagreement in the literature over whether it promotes stemness or 
differentiation in myoblasts73,86–88. The combination of these factors can result in imbalances in 
the myoblast population that can lead to exhaustion of the population, or, through interactions 
with other factors, overcrowding of the stem cell niche. As mentioned previously, inflammatory 
cells also play a key role in the fibrotic microenvironment, with persistence of the M1 
macrophage population55. M2 macrophages also become elevated in dystrophic muscle, though 
this activity is insufficient to clear fibrosis89. Furthermore, M2 macrophages may actually 
contribute to the fibrotic microenvironment, as they produce a significant fraction of 
inflammatory cell derived TGF-β, thus promoting pro-fibrotic signalling90. With regards to other 
inflammatory cells, mice which have had their T and B cell populations depleted experience 
reduced fibrosis compared to control animals91. Although several cell types are responsible for 
the production of extracellular matrix in healthy skeletal muscle, the major cell candidate for 
type I collagen production, and basal lamina protein production in general, are fibro/adipogenic 
progenitor (FAP) cells73,92. After proliferating to support normal repair, FAP cells apoptose, but 
in the case of fibrosis, they remain chronically elevated without this apoptotic event93–95. This 
apoptosis is driven by tumour necrosis factor (TNF), but can be halted by overexpression of 
TGF-β, as takes place in fibrosis96. FAP cells are able to differentiate into adipocytes or 
myofibroblasts73,93. During fibrosis, it suggested that myofibroblasts can arise from many cells 
types besides FAP cells alone, including pericytes, resident fibroblasts, fibrocytes, endothelial 
cells, and epithelial cells, as well as locally specific cell types such as myoblasts84,97,98. 
Both the mechanical properties and the composition of the extracellular matrix are altered 
in fibrosis. Collagen content typically increases in fibrosis, with a greater degree of cross-linking, 
resulting in a dense collagen network80,99,100. DMD patients have additionally shown to have 
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several proteoglycans, the proteins responsible for water retention and viscous mechanical 
properties, enriched in their tissue101. Fibronectin is also increased in cases of DMD73,102. The 
secretion of matrix metalloproteinases (MMP)s into the extracellular matrix rises, and deletion of 
particular MMPs, such as MMP-9, has been shown to reduce levels of fibrosis103,104. The 
combination of these changes results in an extracellular matrix which is much stiffer than in 
healthy conditions. This not only reduces the function of the surrounding muscle tissue, but also 
has downstream effects due to the deleterious changes in mechanoregulation this has in other cell 
types. Stiffness has been shown to prompt macrophages to adopt a more M1 phenotype, and 
prevent differentiation and formation of contractile sarcomeres in myoblasts73,105–107. The 
recognition of the fact the microenvironment in DMD is transformed into one contributing to 
fibrosis is of vital importance, as it enables the tailoring of therapies to be able to function 
despite this impediment. 
1.1.7 Detection of Fibrosis in DMD 
In order to determine the progression of fibrosis, biopsy is often considered the gold 
standard for staging purposes108,109. Although this method does allow accurate assessment of 
fibrosis stage, it also comes with key downsides in the form of invasivity and limited 
accessibility. In some patient groups, biopsy may be considered an unnecessary risk due to 
complicating factors such as the chance of infection, or lasting damaging which the biopsy may 
produce. This is a concern for DMD patients7,110. Investigating other methods to analyze fibrosis, 
such as the use of imaging technologies or serological markers, is therefore pertinent. 
With regards to current imaging technology, this takes several forms. Magnetic resonance 
imaging (MRI) is able to effectively resolve muscle, fat, and connective tissue, but suffers from 
difficulties separating fat from water. There is current work being done on fat suppression 
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techniques that allow better resolution of increased water content brought about by 
inflammation81,111,112. Unfortunately, equipment for MRI is often prohibitively expensive, and 
may not necessarily be available for DMD patients to use. Elastography-based techniques, which 
evaluate tissue stiffness using MRI or ultrasound imaging of mechanical sheer waves113, and 
impedantometry, which examines tissue water content through propagation of electrical current, 
are both promising new techniques to examine muscle tissue114,115. However, little work has been 
conducted examining their use in DMD patients. Similarly, myography, which involves 
examining the physical properties of near-surface muscle through palpation, also shows promise, 
but requires investigation with regards to specific applications in DMD patients81,116. Positron 
emission tomography-computed tomography (PET-CT) techniques, combining modern imaging 
with radiolabeled substances which localize to fibrotic regions, have also seen some exploration 
in recent years117. However, little focused has been placed on PET-CT in DMD patients. In 
general, these imaging techniques are still in development, and may require combination with 
serological marker evaluation to accurately gather information about fibrosis. 
In terms of current serological markers for fibrosis, a great deal of focus has been placed 
on liver and cardiac fibrosis markers, with a lesser, though still considerable, amount of analysis 
on skeletal muscle fibrosis markers. There have been several large-scale studies on markers in 
DMD patient and mouse model sera. A 2014 study which evaluated 355 mouse sera proteins 
found 23 which were significantly elevated in the Mdx mouse model, of which twenty were also 
elevated in serum derived from human DMD patients. These could be divided into several 
categories, and primarily consisted of glycolytic enzymes, transport proteins, and myofibrillar 
proteins. There were several possible candidate proteins detected which had links to fibrosis, as 
opposed to muscle degeneration alone. Some examples include thrombospondin 4 (TSP4), an 
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extracellular remodeling protein, and matrix metalloproteinase 9 (MMP9), an extracellular 
protease118. MMP9 has been previously correlated with DMD disease severity over time in 
patients119. Another study analyzing DMD and BMD patients found similar results with regards 
to markers of muscle degeneration, but elucidated difficulty with regards to separating cases of 
DMD from BMD utilizing MMP9 alone. It did not examine TSP473,120. Exploration of these and 
similar markers in the future is vital to accurately determine levels of fibrosis. Combining 
multiple markers into a panel-based measure may be necessary.  
1.1.8 Treatment 
There are several treatments available for DMD. Corticosteroids are most commonly 
used to increase muscle strength and slow rate of decline, but often have complications. Other 
drug therapies, such as anabolic steroids and immunosuppressive agents, which attempt 
respectively to boost muscle strength, and prevent inflammatory responses, are in early stages of 
exploration. Respiratory dysfunction often results in repeated infections, necessitating chest 
physiotherapy and antibiotic use4,7–9. Cardiac symptoms also require monitoring, though 
treatment of these is limited to beta blockers and angiotensin converting enzyme inhibitors7. 
Despite advances in physical therapies and steroid treatments, no cure or long-term treatment for 
DMD has been found.  
Several promising new therapies have also appeared in recent years, primarily in the form 
of gene therapy variants. Some of the most common versions of these are viral vector strategies, 
which normally make use of recombinant adeno-associated viral vectors carrying components of 
the dystrophin gene. These are capable of restoring some dystrophin expression in mouse 
models. However, the size of the dystrophin gene creates challenges for this therapy, as the 
normal gene is too large to be transported within adeno-associated virus. Attempts have been 
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made to supply truncated, but still functional, versions of the gene. However, many of these 
attempts result in either sacrifice of some dystrophin gene functions, or reduced transduction 
efficiency121,122. Nonetheless, there are ongoing clinical trials utilizing this technique, such as 
with rAAVrh74.MHCK7.micro-dystrophin or PF-06939926123. Another strategy which still 
utilizes adeno-associated viral vectors is CRISPR/Cas9 delivery. This can be targeted toward 
single mutations bringing about DMD, and past studies have showed some success in mouse 
models. This has included measures such as force generation, evaluation of CK level, and 
histological examinations such as rate of tissue necrosis121,124–126. Nonetheless, these strategies 
still face problems, generally associated with delivery and specificity. Fibrotic environments, 
such as those found in DMD, often have reduced blood perfusion, and therefore poorer delivery 
of viral carriers. Effectively targeting adeno-associated virus to a single cell type can also be 
challenging, Additionally, these strategies do not directly target the muscle microenvironment or 
the fibrosis that is associated with DMD. Even if these treatments were successful, loss of 
muscle strength may persist for months, or last indefinitely. Drugs which induce exon-skipping, 
such as Eteplirsen, are also under investigation127. These produce partially-functional dystrophin 
which ignores critically mutated exons. Unfortunately, only cases with mutations in particular 
vulnerable exons are possible candidates for this form of treatment. Stem cell therapy has been 
considered in the past as a possible treatment for DMD, but complications have arisen due to the 
nature of the therapy. Nonetheless, novel methods to adjust the therapy to make it suitable for 
DMD are still being studied. Stem cell therapy involves supplying DMD patients with new 
muscle stem cells which produce dystrophin, and which can replace their normal dystrophin null 
stem cells. However, immune responses to myogenic stem cells derived from donor sources limit 
their applicability, as the body may destroy these before any therapeutic benefit is yielded. 
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Additionally, the stem cell niche, which enables stem cell proliferation and differentiation, can 
often be destroyed through the process of fibrosis73,128,129. Autologous myogenic stem cell 
sources are a possible solution to the immune response issue. Ex vivo gene correction 
techniques, such as chimeraplasty and small fragment homologous replacement therapy, can be 
used prior to expansion of these myogenic stem cell colonies. These can then be transplanted 
back into the host from which the cells were derived. Unfortunately, dystrophic muscle often has 
a low population of myogenic stem cells, making it difficult to extract a sufficient number to 
begin this process121,130–132. Even techniques involving bone marrow-derived stem cells with 
myoremodeling capacity need other measures to acquire a sufficiently large population133. 
Satellite cell transplantation has been shown to be improved by initial treatment with a 
neutralizing antibody against connective tissue growth factor73,134. It is clear that these upcoming 
techniques still require refinement before being candidates for DMD treatment.  
Another group of upcoming therapies, rather than focusing on correcting mutations in the 
dystrophin gene, attempt to address the fibrosis associated with the condition. Anti-inflammatory 
drugs, such as TNF inhibitors, and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) inhibitors, are possible candidates to be repurposed for an antifibrotic role81,135.  
TGF-β is a possible target for this therapy. In radiation-induced fibrosis in cancer 
treatment, and in scleroderma cases, halofuginone is able to block the canonical TGF-β pathway, 
inhibiting synthesis of type I collagen, slowing fibrosis73,74. Another activator of the MAPK and 
SMAD pathways is the renin-angiotensin system, where angiotensin-converting enzyme 1 
(ACE1)-mediated conversion of angiotensin I into angiotensin II allows it to bind to the 
angiotensin II (AT1/2) receptors, which can promote these pathways136. Inhibitors of ACE1, 
such as Enalapril and Lisinopril, and the AT1/2 blocker Losartan, are all potential antifibrotic 
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treatments73,137–139. Nitric oxide enhancers such as the phosphodiesterase 5 inhibitor sildenafil 
may also serve a role, as hypoxia has been shown to increase fibrosis, and treatment with these 
enhancers may reduce it140. Antioxidants such as idebenone141 and resveratrol142, and 
mineralocorticoid antagonists like eplerenone81,143, are also possible candidates. Combining 
nutrition, physiotherapy, and temperature-based techniques with these drugs can create a holistic 
approach to addressing fibrosis in DMD patients81. However, additional research will need to be 
conducted in order to determine how applicable these drugs are for use in DMD patients, and at 
what stages of fibrosis they can be used at.  
This suggests two major directions in which to continue research. Firstly, to develop new 
treatments aimed at improving the microenvironment and reducing fibrosis. Secondly, to develop 
techniques to identify areas that will become fibrotic before permanent damage takes place. To 
meet these goals, it is necessary to identify biomarkers of the fibrotic microenvironment. 
1.1 Wilms’ Tumour 1 (Wt1) 
1.1.1 Overview 
Wilms’ Tumour 1 (Wt1) is a zinc-finger transcription factor with additional roles in post-
transcriptional regulation, and control of other transcription factors. In mammals, the gene is 
composed of ten exons, and is approximately 50 kb in length144. The human protein Wt1 was 
originally identified in Wilms’ tumour, but has since been implicated as a factor in multiple other 
conditions, such as the Denys-Drash and Frasier syndromes144–146. It has numerous isoforms, 
which act in related but distinct cellular roles. Twenty-four different forms of Wt1 protein have 
been identified in murine and human models. However, recent research suggests that there are 
additional Wt1 isoforms which have so far been uncharacterized in the literature147,148. The 
different Wt1 isoforms arise primarily from alternative starts sites where translation of Wt1 
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protein takes place, and from alternative splicing, though there is some evidence that RNA 
editing may also play a role148,149.  
1.1.2 Wt1 Expression during Development 
Wt1’s most well-known functions, apart from pathogenesis, are its roles in the regulation 
of mammalian embryonic development. Wt1 has been found to have roles in several major organ 
systems, most prominently the gonads and kidneys, but also the cardiac, nervous, and respiratory 
systems. In mice with mutations in their Wilms’ tumour 1 gene, Wt1, these organs often develop 
poorly, or not at all, resulting in embryonic lethality148,150–152. 
In the gonads and adrenal glands, Wt1 serves a variety of roles. It has been shown to 
reduce Leydig cell formation while promoting Sertoli cell differentiation through its promotion 
of the sex-determining region Y (SRY) gene153. Mice which are Wt1 null fail to develop adrenal 
glands or the gonads154. In kidney development, Wt1 is expressed in the metanephric 
mesenchyme. There are multiple Wt1 target genes vital for proper mesenchymal function during 
this stage, including spalt-like transcription factor 1 (Sal1), bone morphogenetic protein 7 
(Bmp7), and paired box gene 2 (PAX2). Wt1 also controls several other key regulators of 
mesenchymal proliferation and apoptosis144,155,156. Not only does Wt1 maintain the mesenchyme 
of the developing kidney, it also supports the formation of the proximal nephron and podocytes. 
Wt1 expression becomes localized to the arising nephron during nephrogenesis, and eventually is 
confined to the proximal developing nephron, and then the developing podocytes144,152.  
Wt1 expression during cardiac development is primarily in the epicardium. Eliminating 
expression of the Wt1 mouse protein has been shown to prevent proper cardiac vascularization. 
Wt1 appears to be required for epithelial and mesothelial to mesenchyme transitions, and this 
transition is necessary for epicardial derived coronary vascular cell progenitor formation144,157. 
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Furthermore, Wt1 deletion can cause incomplete formation of the diaphragm, leading to 
herniation of the abdominal organs into the chest cavity144,158.  
1.1.3 Wt1 Expression during Adulthood  
Beyond development, Wt1 and its isoforms also serve functions in adult organisms, 
primarily in the kidneys, gonads, and bone marrow. Deletion of Wt1 in adult mice triggers severe 
glomerulosclerosis in the kidney, as well as bone loss, and atrophy of the spleen and exocrine 
pancreas. Insulin growth factor 1 (IGF1), a regulator for both bone and fat growth, was reduced 
in circulation in these models, suggesting that Wt1 may serve a role in controlling it159. In the 
cortex of the adult adrenal gland, research has indicated the presence of rare Wt1 expressing cells 
which, through adulthood, can still differentiate into steroidogenic cells. Gonadectomy appears 
to stimulate this differentiation144,160. In the kidneys, Wt1 serves roles in regulating nephrin and 
podocalyxin in podocytes144,161,162. Expression of Wt1 additionally takes place in the adult mouse 
heart, serving a role in coronary vascular cell proliferation following ischemia147,163. There is 
evidence that transcription of the Wt1 mouse gene can be directly upregulated by hypoxia-
inducible factor 1 (HIF1)144,164.  
1.1.1 Wt1 Protein Structure 
The role a particular Wt1 isoform fulfills is largely determined by how it has been post-
transcriptionally modified, though there are nonetheless some common functions between 
variants. The capacity for Wt1 to bind certain DNA and RNA sequences is mediated through its 
zinc finger domains, and these are present in all major isoforms, though there is evidence the 
affinity for particular DNA or RNA sequences can differ between different Wt1 isoforms165. Wt1 
isoforms can be divided into four major groups (Fig. 2), defined through their inclusion of exon 
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five (EX5), and through inclusion of a lysine, threonine, and serine (KTS) amino acid sequence 
toward the end of exon nine147. Commonly, the isoforms of Wt1 are referred to as A  
(EX5-/KTS-), B (EX5+/KTS-), C (EX5-/KTS+), and D (EX5+/KTS+). 
Exon five enables interactions with prostate apoptosis response factor 4, by encoding a 
protein-protein interaction domain. This modulates the ability of Wt1 to regulate cell 
proliferation144,166. In the adult mammary glands, exon 5 bearing isoforms are expressed167. 
Furthermore, there is preliminary evidence that exon 5 appears to partially compensate for some 
zinc finger function. Natoli et al. showed that so long as exon 5 is present, both the third and 
fourth zinc fingers of Wt1 can be deleted, with normal viability and kidney histology maintained. 
However, additional work is necessary to confirm this168.   
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Figure 2. Wt1 and Isoforms 
Diagram of Wt1 gene, some of its mRNA products, and the translated protein. Alternative 
translation initiation sites are indicated by the black arrows, alternative splice sites are indicated 
by dark coloration, and an alternate exon produced by an alternative translation initiation site is 
indicated by vertical hatching. Portions of this figure adapted from Kramarzova (2012).  
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The KTS sequence is suspected to be involved with the splicing machinery itself, and its 
regulation. However, the two isoforms do have some degree of overlapping function, as studies 
evaluating developing mice where only one of the two isoforms have been expressed reveal little 
to no differences in the development of the cardiovascular or genitourinary systems. Isoforms 
with the KTS sequence show stronger affinity for insulin growth factor 2 (IGF2) RNA than those 
lacking the sequence. However, those without the sequence still maintain some binding affinity, 
likely mediated through zinc finger activity165,169. This activity can be modulated by post-
transcriptional regulation. Inclusion of the KTS sequence likely limits the ability for Wt1 to bind 
early growth response-1 (EGR1) sequences in the genome. Wt1 increases the stability of p53, 
inhibiting its apoptotic effects170.  This interaction not only has been shown to modulate the 
transcriptional activity of p53, but also that of the Wt1 isoform lacking the KTS sequence171. The 
binding partners of Wt1 may have distinct interactions with it dependent on the particular 
isoform to which they are bound.  
Regardless of the presence of the KTS sequence, Wt1 can bind sequences for several 
other genes, including IGF2, platelet derived growth factor subunit A (PDGF-A), PAX2, and its 
own Wt1 gene sequence. Wt1 is capable of both transcriptional activation and repression, and 
debate is ongoing over which comprises its major role147,172–176. Although Wt1 has many roles in 
the nucleus, it is also found to some extent in the cytoplasm. For example, in developing skeletal 
muscle, myocardium, and the endothelial cells of blood vessels177. One possible explanation for 
this localization is interactions with translation. Wt1 has previously been shown to associate with 
translating polyribosomes, and that regardless of the presence of exon 5 or the KTS sequence, 
this activity is maintained. This may indicate active involvement of Wt1 with the translation of 
protein, or interactions with RNA outside the nucleus178.  
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1.1.2 Wt1 in Fibrosis 
Although its discovery was through its appearance in forms of cancer, recent research has 
shown Wt1 to also be involved with fibrosis, for example, in idiopathic pulmonary fibrosis and 
Dupuytren’s Disease (DD). One 2015 study by Sontake and colleagues showed that Wt1 
expression was present in subpleural fibrotic lesions in the lungs of human idiopathic pulmonary 
fibrosis patients, but not in healthy patients. Cultures of mesenchymal cells taken from these 
tissues showed increased Wt1 transcript presence. When knocked down with siRNA against Wt1, 
these cultures showed significant decreases in production of several extracellular matrix genes. 
Mice which had subpleural fibrotic lesions induced by TGF-α overexpression showed similarly 
increased Wt1 expression in vimentin-positive mesenchymal cells and alpha smooth muscle 
actin (α-SMA) expressing myofibroblasts, though not in fibrocytes. However, fibrocyte infusion 
did appear to increase the number of Wt1 positive cells in mice179. Lineage tracing experiments 
have furthermore shown that Wt1-positive mesothelial cells are a major source of mesenchymal 
cells, and specifically, myofibroblasts, in subpleural fibrotic lung lesions. Transfection with Wt1-
overexpressing lentivirus increased fibroblast-to-myofibroblasts transformations in fibroblast 
cultures derived from mice, and Wt1 knockdown is able to reduce rates of proliferation in 
fibroblast cultures derived from human idiopathic pulmonary fibrosis lung tissue. Partial 
knockout of Wt1 in TGF-α mice is able to reduce lung hydroxyproline levels and improve lung 
compliance, and reduce Masson’s trichrome staining in bleomycin treated wildtype mice180. 
However, other research has run contrary to this narrative. A 2014 study by Karki and colleagues 
found reduced Wt1 expression in idiopathic pulmonary fibrosis lung tissue pleural mesothelial 
cells. Treatment of pleural mesothelial cells with shRNA against Wt1 was found to cause a 
mesothelial to mesenchymal transition, with upregulation of fibronectin and α-SMA, an altered 
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morphology, and increased collagen gel contractility181. Another area of particular interest has 
been research concerning the upregulation of Wt1 expression in primary fibroblasts derived from 
DD. Immunohistochemistry of fibrotic tissues taken from DD patients revealed clusters of cells 
expressing Wt1, and quantitative polymerase chain reaction (qPCR) analysis of Wt1 expression 
in fibroblast cultures derived from these tissues showed upregulation of Wt1 compared to control 
fibroblast cultures. Control cultures in this study were derived from syngeneic fibroblasts, 
suggesting that neither genetic variability or systemic effects were the cause of the Wt1 
upregulation, but that it was brought about by fibrosis itself.182. This suggests that, if it is the case 
that Wt1 is a marker for fibrosis, it may be a marker in several fibrotic disorders, including 
fibrosis induced by DMD. Nonetheless, the literature is currently divided on this topic, so it 
would be worthwhile to gather a deeper understanding of Wt1 overall.  
1.2 Animal Models of DMD 
1.2.1 Dystrophin Knockout Mice 
Numerous animal models of DMD have been engineered, across a range of species, but 
some of the most well-studied have been mice183. Particularly, the X chromosome-linked 
muscular dystrophy (Mdx) mouse, a dystrophin-null model, has received the most examination as 
a model of the disease (Fig. 3). The Mdx mouse model possesses a point mutation in the 
dystrophin gene, resulting in production of no functional dystrophin184.  
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Figure 3. Different Mouse models of Duchenne Muscular Dystrophy 
Representative images of wildtype (A), Mdx (B), Mdx/Utrn+/- (C), and Mdx/Utrn-/- (D) mice. 
Table depicting the number of alleles expressing dystrophin and utrophin, as well as the age 
ranges utilized, for each mouse model (E).  
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There are increased muscle creatine and pyruvate kinases in the Mdx mouse model, 
alongside muscle lesions typical of human DMD patients185. The Mdx model exhibits 
histological features characteristic of muscle degeneration, including centrally-nucleated 
myofibers and the presence of inflammatory infiltrate. Other DMD-like symptoms also occur, 
such as fibrosis, but not as extreme as in the case of most human DMD. Fibrosis is often limited 
to certain muscle groups, such as the diaphragm, with muscle groups like the hind limb 
experiencing negligible fibrosis. Furthermore, the Mdx mouse model exhibits little weakness186–
188. A 2015 study characterized the Mdx model, alongside several others, compared to the 
wildtype. Examination of muscle weakness via a grip duration test, measuring the duration 
which mice can support their body weight by gripping to a mesh, showed only minor deficits in 
the Mdx mouse compared to the wildtype prior to six months of age. Furthermore, after six 
months, the durations both groups could grip the mesh had become indistinguishable. Rotarod 
testing, which evaluates how long a mouse can remain on a rotating rod, found similar results, 
with Mdx mice performing marginally poorer than the wildtype for the first six months of life, 
and then becoming similar to the wildtype thereafter. Triceps myofiber cross-sectional area was 
significantly smaller than the wildtype in the Mdx model until twelve months of age, and the 
distribution of different myofiber areas differed from the wildtype until approximately six 
months of age. Furthermore, the myosin isoforms expressed in this tissue did not differ in the 
Mdx model compared to the wildtype. In the Mdx mouse, density of collagen IV was shown to be 
significantly increased from the wildtype in the triceps after twelve months, though density of 
collagen I was increased from as early as three months189. The Mdx mouse model additionally 
has altered presentation of cardiac symptoms compared to human DMD patients. Cardiac 
fibrosis does not occur in this model until later in life, and furthermore exhibits other differences, 
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such as the absence of hypokinesia and dyskinesia, uniform distribution of the fibrotic material, 
and a reduced amount of fibrosis compared to DMD patients. Additionally, Mdx mice have an 
increased life expectancy compared to DMD patients, with a 25% reduction  in life expectancy 
compared to wildtype mice, in contrast with the 75% reduction from normal life expectancy as 
seen in human DMD patients183,190. This makes the Mdx mouse an incomplete model for DMD, 
as the more severe features of the disease are not accurately represented. It is therefore pertinent 
that other models be utilized, in order to recapitulate the condition as seen in humans more 
clearly.  
1.2.2 Dystrophin and Utrophin Knockout Mice 
The literature suggests that, in mice, the presence of utrophin, a dystrophin homolog, 
provides a compensatory effect which alleviates some of the pathology produced by dystrophin 
loss. In mice, use of a utrophin transgene has been shown to ameliorate pathology caused by the 
absence of dystrophin. Furthermore, muscle regions which normally have high utrophin exhibit 
lower muscle degeneration in mice188,191–193. Knocking out utrophin, either partially, as in the 
case of Mdx/Utrn+/- mice, or totally, as in the case of Mdx/Utrn-/- mice, provides an avenue by 
which pathology more similar to human DMD can be evaluated. 
The Mdx/Utrn+/- model has been shown to experience greater muscle weakness than 
Mdx or wildtype mice. In the 2015 study previously discussed, this was determined by grip 
duration and rotarod testing. Grip duration evaluations showed Mdx/Utrn+/- mice performing at 
less than a quarter of the ability of either the Mdx or wildtype mice at the initial one month of age 
examination point, and they remained lower than both of these other models effectively during 
all evaluation points. Rotarod testing indicated significant deficits for Mdx/Utrn+/- mice 
compared to both Wildtype and Mdx genotypes, until roughly eighteen months of age. The 
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Mdx/Utrn+/- model mice exhibit differences in the distribution of the sizes of their myofibers, as 
well as differences in the expression of myosin isoforms, which are not present in the Mdx 
model. Analysis of deposition of collagen I and collagen IV showed significant increases in this 
deposition compared to the wildtype at all of the age points examined in this study, as well as 
from the Mdx model, except for the 6 month age point for collagen I189. The differences in 
collagen deposition observed have been replicated in other studies, and indicate that particular 
tissues may become fibrotic in the utrophin knockout models which do not become fibrotic in the 
Mdx model. As fibrosis is a significant cause of human DMD patient mortality, this is an 
important feature to focus on189,194. An independent 2012 study showed similar results for 
rotarod and grip duration testing of Mdx mice, though it showed that all of Mdx, Mdx/Utrn+/-, 
and Mdx/Utrn-/- mice perform similar on fore limb grip strength tests. This study additionally 
showed a nonsignificant correlation between the number of utrophin alleles knocked out and the 
expression of inflammatory and fibrotic genes in mouse quadriceps muscle195. Single utrophin 
allele knockout in the Mdx model has been shown to significantly reduce diaphragm function, 
and causes both increased inflammation and fibrosis in the diaphragm and other skeletal muscle 
groups186,187. Some research has indicated that there is a correlation between the number of 
utrophin alleles knocked out, and the increasing presence of centrally-located nuclei indicative of 
muscle fiber regeneration195 
In the Mdx/Utrn-/- model, where there is no utrophin or dystrophin expression, lifespan is 
reduced to 3-4 months, approximately only 11% of the normal lifespan of a wildtype mouse183. 
For the purposes of evaluating these mice, this can be problematic, as it limits long-term studies, 
and complicates animal care and handling. These mice experience severe muscle weakness at an 
age earlier than even that of the Mdx/Utrn+/- model. Examination has shown that these mice are 
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unable to maintain their grip or remain on a rotarod at even one month of age. Furthermore, they 
also experience different expression of myosin isoforms and distribution of myofiber sizes, 
similar to the Mdx/Utrn+/- model. Their collagen deposition is also not significantly different 
than that of the Mdx/Utrn+/- model189. Past research has shown that tibialis anterior muscle 
degeneration is only transient in the Mdx model, while persistent in the Mdx/Utrn-/- model, and 
furthermore that cardiac manifestations are more severe in the Mdx/Utrn-/- model188. Utilization 
of additional Mdx/Utrn+/- and Mdx/Utrn-/- models provides a deeper understanding of disease 
progression.  
1.3 Research Outline 
In this thesis, wildtype, Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice were utilized. 
Collectively, an analysis of all of these genotypes allow exploration of various DMD 
severities194. Furthermore, this study included mice at 4-5 weeks old, 8-10 weeks old, and 10-14 
months old, representing immature, mature, and aged mice. These ages allow an interrogation of 
Wt1 expression changes with respect to the progression of fibrosis over time. Heart, diaphragm, 
and gastrocnemius muscle tissue were examined for these mice, as prior work suggests that 
fibrosis does not arise in all muscle groups in DMD model mice simultaneously, allowing 
examination of these differences. However, only 8-10 week old wildtype and Mdx/Utrn+/- 
gastrocnemius muscles were used to evaluate mRNA expression. This provides examples of non-
fibrotic tissue, in the form of the 8-10 week old wildtype gastrocnemius muscle tissue, and 
fibrotic tissue, in the form of the 8-10 week old Mdx/Utrn+/- gastrocnemius muscle tissue194. 
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2 HYPOTHESIS AND OBJECTIVES 
 
2.1 Hypothesis 
Previous studies indicating that Wt1 is both a marker for fibrosis in DD182 and idiopathic 
pulmonary fibrosis179,180 suggest that Wt1 may be a marker for multiple fibrotic conditions. 
Therefore, this has led to the hypothesis that Wt1 immunoreactivity is a marker for fibrosis in a 
mouse model of DMD.  
2.2 Rationale and Objectives 
1. To evaluate the timing and location of expression of Wt1 with respect to the onset of 
fibrosis in a mouse model of DMD.  
The rationale behind this objective was that it will provide a thorough understanding of 
the changes in Wt1 immunoreactivity throughout the aging process and at multiple levels of 
fibrosis in these models, allowing a comparison with DMD patient fibrosis more accurately. In 
order to address this objective, immunohistochemistry was used to assess Wt1 immunoreactivity 
location, as well as its quantity as a function of the proportion of a tissue and its structures which 
were immunoreactive for Wt1. Furthermore, Masson’s trichrome staining was also used to 
determine the level of fibrosis, and hematoxylin and eosin staining was used to identify 
candidate cell types that Wt1 may be found in. 
2. To determine which isoforms of Wt1 are altered during the onset of fibrosis in a mouse 
model of DMD. 
The rationale behind this objective was that it will elucidate how Wt1 expression changes 
with regards to the particular isoforms that are expressed in fibrotic conditions. This may enable 
more specific targeting in reference to treating isoforms responsible for tissue fibrosis. In order 
to address this objective, qPCR was utilized to assess total Wt1 expression, as well as the fraction 
31 
 
 
 
of the sum of expression of its four major isoforms which each of the four major isoforms was 
responsible for.  
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3 MATERIALS AND METHODS 
 
3.1 Samples 
3.1.1 Animal Care and Tissues 
All animal protocols were approved by the Institutional Animal Use Subcommittee 
(Western University, London, ON, Canada) and conducted according to guidelines set by the 
Canadian Council on Animal Care (CACC); ethics approval documentation can be found in 
Appendix A. Mice were maintained in the Animal Care Facility at St. Joseph’s Health Care 
(SJHC), under controlled conditions (19–23˚C, 12 hour light/dark cycles), and allowed water and 
food ad libitum. Wildtype, Mdx, and Mdx/Utrn+/- mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME), with additional wildtype mice purchased from Charles Rivers. An 
additional portion of the Mdx/Utrn+/- mice were provided by Dr. Robert Grange (Virginia 
Polytechnic and State University), originally generated by Dr.’s Mark Grady and Josh Sanes 
(Washington University, St. Louis)188. Production of Mdx/Utrn-/- mice was conducted by 
breeding together Mdx/Utrn+/- mice. Mice that declined in health, characterized by a loss of 15% 
body mass, lethargy, dehydration, labored breathing, and lack of appetite, were euthanized to 
prevent suffering. Genotyping was conducting by polymerase chain reaction (PCR), using tail 
snips or ear notch tissues.  
Cohorts used in this study consisted of three mice of a particular age range, either 4-5 
weeks old, 8-10 weeks old, or 10-14 months old, as well as a particular genotype, being either 
wildtype, Mdx, Mdx/Utrn+/-, or Mdx/Utrn-/- mice (n = 3 for all groups). However, 10-14 month 
old Mdx/Utrn-/- mice were not utilized due to a short life expectancy prohibiting study. Mice 
from a C57B1/6ScSn and C57B1/10ScSn background were pooled for each cohort. Upon 
reaching the desired age, mice were sacrificed through cervical dislocation following gas 
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euthanasia. Immediately after this, diaphragm, heart, and gastrocnemius muscles were dissected 
and fixed in 10% formalin for 24-48hrs. These tissues were then embedded in paraffin. For some 
of the 8-10 week old wildtype and Mdx/Utrn+/- mice, a second gastrocnemius muscle was 
extracted and either immediately flash frozen, or placed into RNAlater™ (Thermo Fisher 
Scientific) reagent and stored at -20oC, for later RNA extraction.  
3.1.2 Human Tissues 
Human muscle tissue samples were acquired from the University of Maryland Brain and 
Tissue Bank, fixed in 10% formalin, and embedded in paraffin. One sample of skeletal muscle 
from a DMD patient, and one from a healthy control, were used. These were subjected to 
staining in an identical fashion to the mouse tissue blocks, but were used exclusively for 
immunohistochemistry and Masson’s trichrome staining. These samples underwent solely 
qualitative analysis through visual inspection. 
3.2 Histology 
3.2.1 Tissue Preparation 
Immunohistochemical staining (performed in-house) and Masson’s trichrome staining 
(performed at the Pathology Department at University Hospital, London, ON) were performed 
on all cohorts as well as on human DMD patient muscle tissue, with three biological replicates 
for each mouse cohort, and one biological replicate for human samples. Hematoxylin and eosin 
staining (performed at the Molecular Pathology Lab at Robarts Research Institute, London, ON) 
was performed on a single biological replicate for each mouse cohort. Furthermore, three 
technical replicates were utilized for Masson’s trichrome and immunohistochemistry of mouse 
tissues. Single technical replicates were used for human tissues, as well as hematoxylin and eosin 
staining. Sections produced from each block were 5μm in thickness.  
34 
 
 
 
3.2.2 Immunohistochemistry 
For those tissue sections proceeding with immunohistochemistry, a modified protocol 
based on Abcam standards was performed. The sections were first deparaffinized and rehydrated 
in a series of xylene and ethanol washes. This was followed by heat-mediated antigen retrieval in 
a Tris-ethylenediaminetetraacetic acid (EDTA) buffer for 20 minutes. Slides were then cooled 
slowly to room temperature, and incubated in a 3.0% hydrogen peroxide solution for 10 minutes 
to block endogenous peroxide activity. The slides then underwent nuclear permeabilization via 
treatment with 0.3% Triton X-100 in phosphate buffered saline (PBS) for 10 minutes, with an 
additional two washes for five minutes in PBS before and after this treatment. Background 
Sniper (Biocare Medical) was applied for 8.5 minutes as a blocking reagent to reduce non-
specific background staining. Tissue sections were then incubated overnight with either anti-Wt1 
(Abcam, 1:250), or no antibody, the latter as a negative control (Fig. 4). A negative control was 
conducted in this fashion for every tissue stained and quantified (Appendix B-D). The anti-Wt1 
antibody is a rabbit monoclonal antibody against the 50-250 amino acids of the Wt1 protein. As 
a positive control and true negative control one section of mouse kidney was stained with anti-
Wt1. This staining followed the same protocol, alongside each group of slides stained, for those 
slides which would be quantified. Kidney podocyte staining was used as a positive control, while 
negative staining of the medulla was used as a true negative control144 (Fig. 5). Sequential 
dilutions of antibody were tested in order to determine 1:250 as an appropriate working 
concentration. All incubations were conducted in 1% bovine serum albumin (BSA) PBS. After 
washing twice in PBS for five minutes, tissue sections were then incubated with a biotinylated 
secondary antibody (Vector Labs, 1:200) for one hour, and following two additional five minutes 
PBS washes, with ExtrAvidin®−Peroxidase (Millipore Sigma, 1:100). Oxidization of 3,3'-
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diaminobenzidine (DAB), with the substrate left on each sample for 2.5 minutes, was then used 
to visualize these sections, with nuclei counterstained using Carazzi’s hematoxylin. Sample 
diaphragm and gastrocnemius tissue sections derived from 8-10 week old Mdx/Utrn-/- mice then 
underwent eosin staining to enable identification of cell types. Additionally, one sample of each 
tissue type did not undergo Carazzi’s hematoxylin counterstaining (Appendix F-H) 
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Figure 4. Representative images of diaphragm assessed for Wt1 immunoreactivity, 
alongside a negative control, in 8-10 week old Mdx mice. 
An example section of 8-10 week old Mdx diaphragm evaluated immunohistochemically for 
Wt1, with nuclei counterstained using hematoxylin (A). Additionally, the same procedure was 
conducted without primary antibody as a negative control (B). In the bottom left corner, a section 
of magnified nuclei are provided for examination (scale bar = 100μm).  
37 
 
 
 
 
Figure 5. Positive control validation of Wt1 antibody binding in kidney podocytes, and 
negative control validation of Wt1 antibody binding in kidney medulla. 
An example section of 4-5 week old Mdx/Utrn-/- kidney evaluated immunohistochemically for 
Wt1, with nuclei counterstained using hematoxylin. Podocytes immunoreactive for Wt1 can be 
identified in the clustered regions of nuclei indicative of Bowman’s capsules, one of which have 
been identified with arrows, while Wt1 immunoreactive cytoplasm can be identified in the 
proximal portion of developing nephrons (A). Additionally, an image of the medulla of this same 
section, showing no Wt1 immunoreactivity (B) (scale bar = 100μm). 
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3.2.3 Microscopy and Image Analysis  
For imaging of collagen content, and Wt1 DAB stain intensity, images were acquired on 
a Zeiss Axioskop 50 Microscope under a 40x objective, for Wt1, or a 20x objective, for collagen 
content, using Eclipse Image Software. Up to ten images were taken from each tissue section, 
with a minimum of five images. For immunohistochemistry images, care was taken not to image 
regions of fat where false-positive signal was generated due to sequestering of DAB reagents. 
For nuclear Wt1 quantification in tissue sections, nuclei and the number of nuclei positive 
for Wt1 were quantified using Fiji196,197 and QuPath198. Images were pre-processed in Fiji, 
through background subtraction, and manual selection of the tissue component of the image and 
application of a color balancing macro. This was to ensure that nuclei were considered positive 
only if they have darker staining than the surrounding region. Positive nuclei were then 
determined through the positive cell detection module in QuPath, first quantifying the number of 
nuclei by identifying regions of the image which were significantly ‘blue’ compared to the 
background, and then determining if those nuclei were positive for Wt1 by either having a mean 
or max ‘brown’ color above two separate threshold parameters (Fig. 6).  
For muscle cytoplasm and non-muscle tissue quantification, regions of tissue positive for 
Wt1 were assessed using a simple thresholding algorithm in Fiji. Images were pre-processed in 
Fiji, through background subtraction, and manual selection of the non-tissue component of the 
image and application of a color balancing macro. For each image, if possible, separate regions 
of interest were manually outlined containing muscle cytoplasm or non-muscle tissue. This was 
determined through examination of these regions for typical histological features of muscle and 
non-muscle tissues (Appendix E). Images which did not contain one of these regions were not 
included in the evaluation of that region for the respective tissue section. These regions were, 
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after selection, then given a standard threshold, to determine the percent area which is 
sufficiently brown, deemed Wt1 positive. This was conducted for both the experimental sections 
as well as the negative controls for each sample. The negative control signal was subtracted from 
the experimental sections, to yield a true Wt1 immunoreactivity (Appendix B-D). 
Collagen content was assessed across all Masson’s trichrome images for a particular slide 
and automatically quantified using an in-house colour thresholding algorithm written in 
MATLAB 2019b (Mathworks, Natick, MA, USA). Briefly, all images were transformed into 
Lab colour space allowing the isolation of the colour and lightness components of each pixel. A 
k-means clustering algorithm was then applied to the colour components of each individual 
image to partition the pixels into groups of relatively ‘red’ or ‘blue’ colour values. A uniform 
threshold was applied to all images to mask regions with high lightness (appearing as white). 
Finally, morphological closing operations were performed on the ‘red’ and ‘blue’ regions to fill 
any gaps less than 3 pixels in radius. The area of the image which was composed of tissue was 
determined by brightness threshold. The percent of collagen present in each image was 
calculated as the area of the remaining ‘blue’ region divided by the area considered tissue. 
Automatic thresholds were manually verified with labelled colour overlays on the original 
histology images to ensure that collagen presence was accurately identified (Fig. 7).  
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Figure 6. Example division of image into Wt1 immunoreactive and Wt1 non-
immunoreactive nuclei. 
An example of 4-5 week old Mdx/Utrn+/- gastrocnemius stained immunohistochemically for 
Wt1, with nuclei counterstained using hematoxylin. QuPath positive cell detection has identified 
negative nuclei in blue, and positive nuclei in red, with 181 nuclei detected, at a 29.83% 
immunoreactivity rate. Manual quantification by eye found 178 nuclei, at a 26.40% 
immunoreactivity rate (scale bar = 100μm). 
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Figure 7. Quantification of collagen content in Masson's trichrome stained muscle tissue 
sections. 
Sections of 10-14 month old gastrocnemius tissue stained with Masson’s trichrome, either 
wildtype (A) or Mdx/Utrn+/- (C). Images were transformed into Lab colour space, allowing the 
isolation of the colour and lightness components of each pixel. A k-means clustering algorithm 
was then applied to the colour components of each individual image to partition the pixels into 
groups of relatively ‘red’ or ‘blue’ colour values (B, D) (scale bar = 100μm). 
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3.3 Quantification of mRNA 
3.3.1 RNA Extraction and Preparation 
Samples of gastrocnemius tissue up to 50mg in size were weighed and homogenized in 
Trizol Reagent (Ambion), using an Ultra-Turrax T25 Homogenizer. Samples were then 
transferred to Phasemaker Tubes (Invitrogen), mixed with chloroform, and centrifuged at 
16000G at 4oC for 15 minutes. The aqueous layer was then pipetted off into a new tube, 
combined with an equal volume of isopropanol, and incubated for 20 minutes at room 
temperature. Following centrifugation at 16000G at 4oC for 10 minutes, samples were washed 
twice in chilled 70% ethanol, with this centrifugation step repeated at the end of each wash. 
Samples were allowed to dry for 15 minutes after removal of ethanol, and then resuspended in 
40ul RNAse free water through a 10 minute incubation at 60oC. The amount of RNA in these 
samples was then quantified through analysis on a DeNovix DS-11 spectrophotometer. 
RNA was then converted into cDNA using a High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems), in accordance with the manufacturer’s instructions.  
3.3.2 Primer Creation and Validation 
For the purposes of quantifying total Wt1 and its isoforms, the primers and probe 
published by Kramarzova et. al (2012), originally for use in humans, were adopted199. Primers 
and probe were adjusted to match the mouse genome, and ordered from Sigma-Aldrich. This 
consisted of a 6FAM-TAMRA conjugated fluorescent probe, and two groups of forward and 
reverse primers. The first primer group is a primer pair to quantify total Wt1. The second primer 
group are two sets of two primers, one set being forward primers for the presence and absence of 
exon 5, and the other being reverse primers for the presence and absence of the KTS sequence. 
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Combining the primers in the latter group allows amplification of all the major isoforms of Wt1 
(Table 1). These primer combinations were assayed using PCR on a mouse cDNA sample. The 
PCR products were then run on a 2.0% agarose gel in tris-acetate-EDTA (TAE) buffer at 80V. 
After the bands had been adequately separated, those bands reflecting the molecular weight of 
the PCR products were extracted and processed using the QIAEX II gel extraction kit according 
to the manufacturer’s instructions. The PCR products were then sequenced (performed at the 
DNA Sequencing Facility at Robarts Research Institute, London, ON) to confirm that the correct 
region of the genome was being amplified.  
3.3.3 qPCR 
With three technical replicates each, qPCR runs for total Wt1, as well as for each major 
Wt1 isoform, were conducted for 8-10 week old wildtype and Mdx/Utrn+/- gastrocnemius 
samples. The qPCR and fluorescence quantification was conducted using the QuantStudio5 
system, with Taqman Fast Advanced Master Mix (Applied Biosystems) used for the reaction. 
The reactions were considered positive if at least one of the technical replicates yielded 
fluorescent signal. Wt1 isoform fluorescence was normalized as a fraction of the sum of all 
isoforms for a particular sample. Total Wt1 was normalized based on the geometric mean of 
three control genes: glyceraldehyde 3-phosphate dehydrogenase (Gapdh), β-Actin (Actb), and 
Cyclophilin A (Ppia). These were chosen due to their past history of use as control genes for 
examination of RNA in the Mdx mouse, as well as their individual efficiencies and the geometric 
mean’s efficiency being similar to that of the primers used to quantify total Wt1 (Appendix I).  
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Table 1. qPCR primers and probes for total Wt1 and major isoforms 
Table listing the sequences for the primers and probes used in this experiment. Exons spanned by 
primers or probes are defined below the relevant sequence by arrows. Bases which have been 
changed between human and mouse primers and probe are underlined, showing conversion of 
human sequence into homologus mouse sequence. Portions of this figure adapted from 
Kramarzova (2012).  
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3.4  Data Analysis 
For quantified images, one of two analysis techniques were used. For comparisons 
between the wildtype and disease models within an age group, a standard one-way analysis of 
variance (ANOVA) was performed. If significant differences were detected, this was followed 
by Bonferroni’s post-hoc test to determine differences between the wildtype and disease models. 
For comparisons between age groups and tissue types, Brown-Forsythe and Welch ANOVA 
tests, and Welch’s t-tests, were used. Where significant differences were found in the former 
case, Dunnett’s T3 multiple comparison test was used to determine differences between different 
age groups and tissue types. In both forms of ANOVA analysis, data are assumed to be normally 
distributed, with each sample independent from each other. However, in the case of comparing 
samples at different time points, the third requirement for standard ANOVA, that there be equal 
variances between treatments, may be violated here. With increased age, there is more time for 
samples to diverge, hence older samples would have more variance than younger samples, and so 
this assumption would be violated. Different tissue types may diverge within an animal at 
different rates as well, so they would not have consistent variances between them. Hence, 
Brown-Forsythe and Welch ANOVA, or Welch’s t-tests, which compensates for this, must be 
utilized. A two-way ANOVA was additionally conducted, to evaluate the strength of associations 
of time and genotype to the outcomes analyzed, though this does not account for the differences 
in variation (Appendix J). 
For qPCR, student’s t-tests were used to compare the differences in the mean expression 
of Wt1 and its isoforms between the 8-10 week old wildtype and Mdx/Utrn+/- gastrocnemius 
tissue. Differences between groups were considered significant at a p-value less than 0.05. 
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4 RESULTS 
 
4.1 Relative to the age-matched wildtype, the proportion of Wt1 
immunoreactive nuclei is increased in the absence of collagen 
deposition in 4-5 week old mouse skeletal muscle 
In order to determine whether the proportion of Wt1 immunoreactive nuclei was 
increased in the absence of collagen deposition in disease model muscle, gastrocnemius, 
diaphragm, and heart muscle in 4-5 week old wildtype, Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice 
were evaluated, examining general histology (Fig. 8), tissue collagen deposition (Fig. 9), and 
nuclei positive for Wt1 (Fig. 10) .  
Evaluation of general histological features of these gastrocnemius (Fig. 8A, D, G, J), 
diaphragm (Fig. 8B, E, H, K), and heart (Fig. 8C, F, I, L) tissues was conducted to determine 
patterns in tissue organization and nuclear Wt1 immunoreactivity. Primarily peripheral nuclei 
were observed in wildtype diaphragm and gastrocnemius tissues (Fig. 8A-B). Central nuclei, 
typical of regenerating skeletal muscle, were observed in all disease models, in both the 
diaphragm and gastrocnemius (Fig. 8D-E, G-H, J-K). However, particularly for the Mdx model, 
these myofibers with central nuclei were uncommon (Fig. 8D, E). Histology characteristic of 
inflammatory infiltrate, such as increased cellularity and polymorphonuclear cells, was visible in 
both the Mdx/Utrn+/- and Mdx/Utrn-/- model skeletal muscle (Fig. 8G-H, J-K), while none was 
found in the wildtype model (Fig. 8A-B). Nuclear Wt1 immunoreactivity was often observed to 
be more abundant than that of the surrounding muscle in these regions (Fig. 10J). However, the 
presence of these infiltrates alone did not appear to prompt nuclear Wt1 immunoreactivity. 
Muscle cells undergoing active degeneration were common in skeletal muscle of all disease 
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models (Fig. 8D-E, G-H, J-K). Tissue morphology characteristic of the presence of adipocytes 
was observed only in Mdx/Utrn+/- and Mdx/Utrn-/- diaphragm tissue (Fig. 8H, K). In contrast to 
the skeletal muscle, the heart muscle examined showed negligible pathological changes at this 
age (Fig. 8F, I, L).  
At this age, the diaphragm exhibited a significant increase in collagen deposition in the 
Mdx/Utrn-/- (p = 0.019) model compared to the wildtype, as well as significant increases in 
proportion of Wt1 immunoreactive nuclei in the Mdx (p = 0.021), Mdx/Utrn+/- (p = 0.048) and 
Mdx/Utrn-/- (p = 0.003) models. The gastrocnemius exhibited statistically significant collagen 
deposition in the Mdx/Utrn+/- model (p < 0.001), and significant increases in proportion of Wt1 
immunoreactive nuclei in the Mdx/Utrn+/- (p < 0.001) and Mdx/Utrn-/- (p < 0.001) models. The 
heart exhibited neither significant differences in collagen deposition nor changes in proportion of 
Wt1 immunoreactive nuclei across all models assessed (p > 0.050) (Fig. 11A-C).  
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Figure 8. Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice demonstrate histopathological changes 
in the diaphragm and gastrocnemius at 4-5 weeks of age.  
Gastrocnemius, diaphragm, and heart muscle was acquired from 4-5 week old mice of several 
genotypes, and stained with hematoxylin and eosin (H&E) to characterize general muscle 
histology. Representative H&E stained sections for wildtype (A-C), Mdx (D-F), Mdx/Utrn+/- 
(G-I), and Mdx/Utrn-/- (J-L) mice (scale bar = 100μm) One biological and one technical 
replicate was used. 
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Figure 9. Mdx/Utrn+/- gastrocnemius muscle and Mdx/Utrn-/- diaphragm muscle 
demonstrate collagen deposition at 4-5 weeks of age.  
Gastrocnemius, diaphragm, and heart muscle was acquired from 4-5 week old mice of several 
genotypes, and stained with Masson’s trichrome to distinguish collagen deposition (blue) from 
muscle (red). Representative images of Masson’s trichrome stained muscle are shown for 
wildtype (A-C), Mdx (D-F), Mdx/Utrn+/- (G-I), and Mdx/Utrn-/- (J-L) mice (scale bar = 
100μm). Three biological and three technical replicates were used. 
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Figure 10. Relative to the age-matched wildtype, there is an increase in number of Wt1 
immunoreactive nuclei in the Mdx diaphragm, as well as both the Mdx/Utrn+/- and 
Mdx/Utrn-/- diaphragm and gastrocnemius, at 4-5 weeks of age.   
Gastrocnemius, diaphragm, and heart muscle was acquired from 4-5 week old mice and assessed 
for Wt1 immunoreactivity. Representative images of Wt1 IHC analysis of muscle are shown for 
wildtype (A-C), Mdx (D-F), Mdx/Utrn+/- (G-I), and Mdx/Utrn-/- (J-L) mice. In the bottom left 
corner, a section of magnified nuclei are provided for examination. Asterisks indicate large 
example regions containing cells resembling inflammatory infiltrate (scale bar = 100μm). Three 
biological and three technical replicates were used. 
 
51 
 
 
 
 
Figure 11. Relative to age-matched wildtype, there is an increased proportion of Wt1 
immunoreactive nuclei in the absence of collagen deposition in 4-5 week old skeletal 
muscle, as examined in wildtype, Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice. 
Following immunostaining or Masson’s trichrome staining, percent of tissue area composed of 
collagen, and percent of nuclei positive for Wt1, was determined, and is expressed as mean +SD. 
This is displayed for the gastrocnemius (A), diaphragm (B), and heart (C). Asterisks indicate 
significant differences with wildtype (* < 0.050, ** < 0.010, *** < 0.001). Three biological and 
three technical replicates were used. 
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4.2 Relative to the age-matched wildtype, the proportion of Wt1 
immunoreactive nuclei is increased during early collagen deposition 
in 8-10 week old mouse skeletal muscle 
That the proportion of Wt1 immunoreactive nuclei was increased in Mdx/Utrn-/- 
diaphragm and Mdx/Utrn+/- gastrocnemius at 4-5 weeks of age despite significant collagen 
deposition suggested that this increase might persist during early collagen deposition. To explore 
this, gastrocnemius, diaphragm, and heart muscle in 8-10 week old wildtype, Mdx, Mdx/Utrn+/-, 
and Mdx/Utrn-/- mice were evaluated for general histology (Fig. 12), collagen deposition (Fig. 
13), and nuclei positive for Wt1 (Fig. 14).  
Once again, gastrocnemius (Fig. 12A, D, G, J), diaphragm (Fig. 12B, E, H, K), and heart 
(Fig. 12C, F, I, L) tissue general histology was evaluated. Wildtype skeletal muscle showed 
primarily peripheral nuclei (Fig. 12A-B), with central nuclei observed in all disease model 
skeletal muscle (Fig. 12D-E, G-H, J-K). To a small extent in the Mdx model, and to a greater 
extent in both the Mdx/Utrn+/- and Mdx/Utrn-/- models, histology was exhibited in skeletal 
muscle which was characteristic of inflammatory infiltrate, such as increased cellularity and 
polymorphonuclear cells (Fig. 8G-H, J-K). In these inflammatory infiltrate candidate regions, 
nuclear Wt1 immunoreactivity was often observed to be higher than that of the surrounding 
muscle. However, the presence of these infiltrates did not alone appear to prompt Wt1 expression 
(Fig. 14E, J). Muscle cells undergoing active degeneration were common in skeletal muscle of 
all disease models (Fig. 12D-E, G-H, J-K). Tissue morphology characteristic of the presence of 
adipocytes was observed only in Mdx/Utrn+/- and Mdx/Utrn-/- diaphragm tissue (Fig. 12H, K). 
In contrast to the skeletal muscle, the heart muscle examined showed negligible pathological 
changes at this age (Fig. 12F, I, L). 
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At this age, the diaphragm exhibited significant increases in collagen deposition in the 
Mdx/Utrn+/- (p = 0.006) and Mdx/Utrn-/- (p < 0.001) models compared to the age-matched 
wildtype control, and showed significant increases in the proportion of Wt1 immunoreactive 
nuclei in the Mdx (p < 0.001), Mdx/Utrn+/- (p = 0.004), and Mdx/Utrn-/- (p < 0.001) models. 
The gastrocnemius exhibited statistically significant increases in collagen deposition in the 
Mdx/Utrn+/- (p < 0.001) and Mdx/Utrn-/- (p = 0.001) models, and showed a significantly 
increased proportion of Wt1 immunoreactive nuclei in the Mdx/Utrn+/- (p < 0.014) model. The 
heart exhibited neither significant differences in collagen deposition nor changes in the 
proportion of Wt1 immunoreactive nuclei (p > 0.050) (Fig. 15A-C).  
This corroborates past research in the Hoffman lab which describe the diaphragm and 
gastrocnemius muscles of these mice models at these ages, indicating a fibrotic phenotype at a 
similar timepoint194.  
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Figure 12. Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice demonstrate histopathological changes 
in the diaphragm and gastrocnemius at 8-10 weeks of age.  
Gastrocnemius, diaphragm, and heart muscle was acquired from 8-10 week old mice of several 
genotypes, and stained with hematoxylin and eosin (H&E) to characterize general muscle 
histology. Representative H&E stained sections for wildtype (A-C), Mdx (D-F), Mdx/Utrn+/- 
(G-I), and Mdx/Utrn-/- (J-L) mice (scale bar = 100μm). One biological and one technical 
replicate was used. 
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Figure 13. Mdx/Utrn+/- and Mdx/Utrn-/- gastrocnemius muscle and diaphragm muscle 
demonstrate collagen deposition at 8-10 weeks of age.  
Gastrocnemius, diaphragm, and heart muscle was acquired from 8-10 week old mice of several 
genotypes, and stained with Masson’s trichrome to distinguish collagen deposition (blue) from 
muscle (red). Representative images of Masson’s trichrome stained muscle are shown for 
wildtype (A-C), Mdx (D-F), Mdx/Utrn+/- (G-I), and Mdx/Utrn-/- (J-L) mice (scale bar = 
100μm). Three biological and three technical replicates were used. 
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Figure 14. Relative to the age-matched wildtype, there is an increase in number of Wt1 
immunoreactive nuclei in Mdx, Mdx/Utrn+/- and Mdx/Utrn-/- diaphragm, and Mdx/Utrn+/- 
gastrocnemius, at 8-10 weeks of age.   
Gastrocnemius, diaphragm, and heart muscle was acquired from 8-10 week old mice and 
assessed for Wt1 immunoreactivity. Representative images of Wt1 IHC analysis of muscle are 
shown for wildtype (A-C), Mdx (D-F), Mdx/Utrn+/- (G-I), and Mdx/Utrn-/- (J-L) mice. In the 
bottom left corner, a section of magnified nuclei are provided for examination. Asterisks indicate 
large example regions containing cells resembling inflammatory infiltrate (scale bar = 100μm). 
Three biological and three technical replicates were used. 
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Figure 15. Relative to the age-matched wildtype, there is an increased proportion of Wt1 
immunoreactive nuclei during early collagen deposition in skeletal muscle, as examined in 
8-10 week old wildtype, Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice. 
Following immunostaining or Masson’s trichrome staining, percent of tissue area composed of 
collagen, and percent of nuclei positive for Wt1, was determined, and is expressed as mean +SD. 
This is displayed for the gastrocnemius (A), diaphragm (B), and heart (C). Asterisks indicate 
significant differences with wildtype (* < 0.050, ** < 0.010, *** < 0.001). Three biological and 
three technical replicates were used. 
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4.3 Relative to the age-matched wildtype, the proportion of Wt1 
immunoreactive nuclei is not increased during late collagen deposition 
in 10-14 month old mouse skeletal muscle 
Finally, it was important to determine whether the increase in proportion of Wt1 
immunoreactive nuclei remained during late collagen deposition in skeletal muscle. Therefore, 
10-14 month old wildtype, Mdx, and Mdx/Utrn+/- gastrocnemius, diaphragm, and heart muscle 
proportion of Wt1 immunoreactive nuclei and tissue collagen deposition were quantified. To 
explore this, gastrocnemius, diaphragm, and heart muscle in 10-14 month old wildtype, Mdx, 
Mdx/Utrn+/-, and Mdx/Utrn-/- mice were evaluated for general histology (Fig. 16), tissue 
collagen deposition (Fig. 17) and nuclei positive for Wt1 (Fig. 18).  
General histological features of these gastrocnemius (Fig. 16A, D, G, J), diaphragm (Fig. 
16B, E, H, K), and heart (Fig. 16C, F, I, L) tissues were examined, once again showing primarily 
peripheral nuclei in wildtype skeletal muscle tissues (Fig. 16A-B) and central nuclei in all 
disease model skeletal muscle (Fig. 16D-E, G-H). Histology characteristic of inflammatory 
infiltrate, such as increased cellularity and polymorphonuclear cells, were common in the 
skeletal muscle of the Mdx/Utrn+/- model, and to a lesser extent in the Mdx model (Fig. 16D-E, 
G-H). However, no differences were found in Wt1 immunoreactivity patterns across these 
regions. Muscle cells undergoing active degeneration were found in the skeletal muscle of all 
disease models (Fig. 16D-E, G-H). Tissue morphology consistent with adipocyte presence, was 
present in disease model skeletal muscle, aside from the Mdx gastrocnemius (Fig. 16E, E-H). All 
disease models showed muscle cells undergoing active degeneration (Fig. 16D-E, G-H). The 
Mdx/Utrn+/-, but not Mdx, heart, was observed to have small, localized regions of inflammatory 
infiltrate and fatty deposition (Fig. 16I). 
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At this age, the diaphragm exhibited significant tissue collagen deposition in the Mdx (p 
< 0.001) and Mdx/Utrn+/- (p < 0.001) models, compared to the wildtype, but did not show 
differences in the proportion of Wt1 immunoreactive nuclei (p > 0.050). The gastrocnemius 
exhibited a statistically significant increase in collagen deposition in only the Mdx/Utrn+/- model 
(p < 0.001), but similarly did not show differences in proportion of Wt1 immunoreactive nuclei 
(p > 0.050). The heart exhibited neither significant differences in collagen deposition nor 
changes in proportion of Wt1 immunoreactive nuclei (p > 0.050) (Fig. 19A-C).  
In all of the tissues which would become fibrotic by the 10-14 month old timepoint, those 
being the Mdx diaphragm, as well as the Mdx/Utrn+/- and Mdx/Utrn-/- diaphragm and 
gastrocnemius, there was a statistically significant increase in proportion of Wt1 immunoreactive 
nuclei at the 4-5 week old timepoint.  
The patterns of fibrosis described here corroborates past research in the Hoffman lab 
which describe the diaphragm and gastrocnemius muscles of these mice models at these ages, 
indicating a fibrotic phenotype at a similar timepoint194.  
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Figure 16. Mdx and Mdx/Utrn+/- mice demonstrate histopathological changes in the 
diaphragm and gastrocnemius, and Mdx/Utrn+/- mice additionally in the heart, at 10-14 
month of age. 
Gastrocnemius, diaphragm, and heart muscle was acquired from 10-14 month old mice of 
several genotypes, and stained with hematoxylin and eosin (H&E) to characterize general muscle 
histology. Representative H&E stained sections for wildtype (A-C), Mdx (D-F), and 
Mdx/Utrn+/- (G-I) mice (scale bar = 100μm). One biological and one technical replicate was 
used. 
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Figure 17. Mdx and Mdx/Utrn+/- mice demonstrate collagen deposition in the diaphragm, 
and Mdx/Utrn+/- mice additionally in the gastrocnemius, at 10-14 month of age. 
Gastrocnemius, diaphragm, and heart muscle was acquired from 10-14 month old mice of 
several genotypes, and stained with Masson’s trichrome to distinguish collagen deposition (blue) 
from muscle (red). Representative images of Masson’s trichrome stained muscle are shown for 
wildtype (A-C), Mdx (D-F), and Mdx/Utrn+/- (G-I) (scale bar = 100μm). Three biological and 
three technical replicates were used. 
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Figure 18. Relative to the age-matched wildtype, there are no differences in number of Wt1 
immunoreactive nuclei in Mdx, or Mdx/Utrn+/- diaphragm, gastrocnemius, or heart, at 10-
14 months of age.   
Gastrocnemius, diaphragm, and heart muscle was acquired from 10-14 month old mice and 
assessed for Wt1 immunoreactivity. Representative images of Wt1 IHC analysis of muscle are 
shown for wildtype (A-C), Mdx (D-F), and Mdx/Utrn+/- (G-I) mice. In the bottom left corner, a 
section of magnified nuclei are provided for examination. Asterisks indicate large example 
regions containing cells resembling inflammatory infiltrate (scale bar = 100μm). Three biological 
and three technical replicates were used. 
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Figure 19. Relative to the age-matched wildtype, there are no differences in proportion of 
Wt1 immunoreactive nuclei during late collagen deposition in skeletal muscle, as examined 
in 10-14 month old wildtype, Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice. 
Following immunostaining or Masson’s trichrome staining, percent of tissue area composed of 
collagen, and percent of nuclei positive for Wt1, was determined, and is expressed as mean +SD. 
This is displayed for the gastrocnemius (A) and diaphragm (B). Asterisks indicate significant 
differences with wildtype (* < 0.050, ** < 0.010, *** < 0.001). Three biological and three 
technical replicates were used. 
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4.4 Wt1 immunoreactivity patterns in muscle cytoplasm and non-muscle 
tissue do not change in mouse skeletal and cardiac muscle, and are not 
significantly different from an absence of expression  
Although Wt1’s principle function is as a transcription factor, it was nonetheless 
important to also characterize its appearance in areas outside the nucleus. Wt1 is also found to a 
degree in the cytoplasm, and furthermore has been shown to possibly be involved in translation, 
such as through interactions with translating polyribosomes177,178.  
The percent of the muscle cytoplasm and non-muscle tissue was thus also evaluated for 
the presence of Wt1 in 4-5 week old (Fig. 10), 8-10 week old (Fig. 14), and 10-14 month old 
(Fig. 18) Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- gastrocnemius, diaphragm, and heart tissue, 
comparing them with age-matched wildtype controls. These analyses were conducted on the 
sections previously presented. 
No statistically significant differences in either the percent area positive for Wt1 in the 
muscle cytoplasm or non-muscle tissue were found (p > 0.050). For several of these tissues, 
subtraction with the negative control showed no area positive for Wt1 whatsoever, and that none 
of the other tissues are significantly different from these suggest that there is no significant Wt1 
immunoreactivity in the muscle cytoplasm or non-muscle tissue (Appendix K).  
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4.5 Proportion of Wt1 immunoreactive nuclei and collagen deposition 
patterns show weak respective trends over time toward decreasing and 
increasing in skeletal muscle  
As collagen deposition has previously been identified to differ between ages and disease 
models, it was important to determine whether the proportion of Wt1 immunoreactive nuclei 
varied over time in skeletal or cardiac muscle, and how this related to collagen deposition194. 
Therefore, the proportion of Wt1 immunoreactive nuclei, as well as well as collagen deposition 
throughout the tissue, were evaluated for 4-5 week old, 8-10 week old, and 10-14 month old 
wildtype (Fig. 20A, C, E), Mdx (Fig. 20B, D, F), Mdx/Utrn+/- (Fig. 20G, I, K), and Mdx/Utrn-/- 
(Fig. 20H, J, L) gastrocnemius, diaphragm, and heart. For each measure, within each tissue and 
genotype, all age points were compared to all other age points. These analyses were conducted 
on the sections previously presented (Fig. 9-10, 13-14, 17-18). 
Of the wildtype tissues, only the gastrocnemius showed significant differences. The 8-10 
week old wildtype gastrocnemius was found to have a significantly higher proportion of Wt1 
immunoreactive nuclei (p = 0.008) than the 10-14 month old wildtype gastrocnemius, though no 
differences (p > 0.050) were found in the wildtype collagen deposition (Fig. 20C). 
With regards to the Mdx tissues, only the diaphragm showed significant differences. The 
8-10 week old Mdx diaphragm was found to have a significantly higher proportion of Wt1 
immunoreactive nuclei than the 10-14 month old Mdx diaphragm (p = 0.004), while the 10-14 
month old Mdx diaphragm was found to have significantly greater collagen deposition than at 
either the 4-5 week old (p = 0.003), or 8-10 week old (p < 0.001) timepoints (Fig. 20B).  
Turning attention to the Mdx/Utrn+/- tissues, both the diaphragm and gastrocnemius 
showed significant differences, though only for collagen deposition. For the gastrocnemius, the 
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10-14 month old tissue was found to have significantly more collagen deposition than both the 4-
5 week old (p = 0.016) and 8-10 week old (p = 0.007) timepoints (Fig. 20I). The 4-5 week old 
Mdx/Utrn+/- diaphragm was found to have significantly less collagen deposition compared to 
the 8-10 week old (p = 0.030) and the 10-14 month old (p = 0.029) diaphragm, and the 8-10 
week old Mdx/Utrn+/- diaphragm was similarly found to have significantly less collagen 
deposition compared to the 10-14 month old (p = 0.037) diaphragm (Fig. 20G).  
Finally, turning focus to the Mdx/Utrn-/- tissue, only the gastrocnemius showed 
significant differences. The 4-5 week old Mdx/Utrn-/- gastrocnemius was found to have a 
significantly higher proportion of Wt1 immunoreactive nuclei (p = 0.012), and lower collagen 
deposition (p = 0.013), compared with the 8-10 week old Mdx/Utrn-/- gastrocnemius (Fig. 20J).  
In contrast to these results, relative to the age-matched wildtype, proportion of Wt1 
immunoreactive nuclear was consistently elevated prior to, or at the same time as, increases in 
collagen deposition throughout affected models, for both forms of skeletal muscle examined. 
However, that the significant differences in proportion of Wt1 immunoreactive nuclei and 
collagen deposition relative to the age-matched wildtype respectively occur earlier, and later, 
would support the results of the time-based analysis (Fig. 22).  
The topic of time-based variation was also examined in the muscle cytoplasm and non-
muscle tissue, with each timepoint compared against each other timepoint within each genotype, 
for the diaphragm, gastrocnemius, and heart. No significant differences were found (p > 0.050) 
(Appendix L). 
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Figure 20. Over time, proportion of Wt1 immunoreactive nuclei, and tissue collagen 
content, show weak relationships toward decreasing and increasing, respectively.   
Graphs depicting proportion of Wt1 immunoreactive nuclei as a percent of nuclei positive, along 
with the collagen content of the tissue as a percent of the tissue, for wildtype (A, C, E), Mdx (B, 
D, F), Mdx/Utrn+/- (G, I, K), and Mdx/Utrn-/- (H, J, L) diaphragm, gastrocnemius, and heart. 
Percent of positive nuclei or tissue area is expressed as mean +SD. Solid lines are used for 
comparisons between collagen at different timepoints, while dotted lines are used for 
comparisons between proportion of Wt1 immunoreactive nuclei at different timepoints. Asterisks 
indicate significant differences (* < 0.050, ** < 0.010, *** < 0.001). Three biological and three 
technical replicates were used. 
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Figure 21. Line-graph summary showing that, relative to the age-matched wildtype, for the 
examined muscles in a model which developed significant collagen deposition, proportion 
of Wt1 immunoreactive nuclei was also significantly increased at either the same, or an 
earlier, timepoint.  
Graphs depicting proportion of Wt1 immunoreactive nuclei as a percent of nuclei positive, along 
with the collagen content of the tissue as a percent of the tissue, for diaphragm (A, B), 
gastrocnemius (C, D), and heart (E, F), of wildtype, Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/-  mice. 
Percent of positive nuclei or tissue area is expressed as a mean. Triangle markers indicate a 
significant difference, with p < 0.050. Three biological and three technical replicates were used. 
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4.6 Collagen deposition, but not Wt1 immunoreactivity patterns, differ 
between healthy diaphragm, gastrocnemius, and heart tissue  
To explore whether Wt1 immunoreactivity differed with respect to the level of collagen 
deposition in different tissues, Wt1 immunoreactivity in the nucleus, muscle cytoplasm, and non-
muscle tissue, as well as collagen deposition throughout the tissue, were compared for 8-10 week 
old wildtype diaphragm, gastrocnemius, and heart. For each measure, each tissue type was 
compared to all other tissue types. These analyses were conducted on the sections previously 
presented (Fig. 9-10, 13-14, 17-18).  
A significantly greater amount of collagen was found in the diaphragm than the heart (p = 
0.003) (Appendix M).  
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4.7 Total Wt1 mRNA is upregulated during early collagen deposition in 
mouse skeletal muscle without a change in the ratios of its major 
isoforms 
In order to determine whether the increase in proportion of Wt1 immunoreactive nuclei 
was accompanied by an increase in Wt1 mRNA, primers were first generated for Wt1 and its 
isoforms. To confirm they amplified the correct sequence, the PCR product of these primers was 
first separated on a gel, extracted, and sequenced (Fig. 22A-B). Following this confirmation, 
qPCR was used to compare expression of Wt1 mRNA in gastrocnemius of 8-10 week old 
Mdx/Utrn+/- mice with the expression in age-matched wildtype control gastrocnemius (Fig. 
22C). There was a statistically significant increase in Wt1 mRNA expression (p = 0.049). 
To examine this question further, it was important to analyze how the individual isoforms 
of Wt1 mRNA varied. Therefore, whether there was a particular Wt1 isoform which was 
upregulated was analyzed, quantifying the mRNA of each isoform in the same tissue as the total 
Wt1 mRNA was quantified (Fig. 22D). However, no significant differences were found in the 
ratios of the isoforms expressed (p > 0.050).  
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Figure 22. Wt1 total mRNA increases with respect to an age-matched wildtype control in 
gastrocnemius muscle of 8-10 week old Mdx/Utrn+/- mice. 
Following PCR amplification, total Wt1 and Wt1 isoform PCR products were separated on 2.0% 
agarose gel (A). Bands at molecular weights corresponding to total Wt1 and each of the Wt1 
isoforms were then excised and sequenced to confirm amplification. Alignment of sequencing 
results on the top with the correct sequences is shown (B). Additionally, graphs are presented 
depicting Wt1 mRNA expression. For total Wt1, this is represented as the concentration relative 
to the wildtype (C). For Wt1 isoform comparison, this is represented as the fraction of the sum of 
the isoforms which a particular isoform makes up (D). Values are expressed as mean +SD. 
Asterisks indicate significant differences with age-matched wildtype. (* < 0.050, ** < 0.010, *** 
< 0.001). Three biological and three technical replicates were used. 
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4.8 Wt1 immunoreactivity in mouse skeletal muscle during early collagen 
deposition is also present in myotubes 
 In order to determine which cell types were immunoreactive for Wt1, an examination of 
differences in histology of 8-10 week old wildtype and Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/-  
diaphragm and gastrocnemius tissues (Fig. 15A-B, D-E, G-H, J-K) was conducted to establish 
changes between tissue which were not dependent on immunostaining. To expand on this, 
immunostaining of diaphragm and gastrocnemius muscle derived from 8-10 week old Mdx/Utrn-
/- mice was followed with counterstaining of this tissue with Carazzi’s hematoxylin and eosin. 
Nuclear Wt1 immunoreactivity was not only limited to the nuclei of cells external to the muscle, 
but also within the nuclei of developing myotubes (Fig. 23A-B).  
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Figure 23. Wt1 immunoreactivity is present in myotube nuclei of eosin counterstained Wt1 
immunostained diaphragm and gastrocnemius of 8-10 week old Mdx/Utrn-/- mice. 
Representative images of 8-10 week old Mdx/Utrn-/- diaphragm (A) and gastrocnemius (B), 
already immunostained for Wt1, which was counterstained with Carazzi’s hematoxylin and 
eosin. In the bottom left corner, a section of magnified immunoreactive nuclei are provided for 
examination. To the right of each image, a section of magnified non-immunoreactive nuclei are 
provided for examination. For further clarity, example immunoreactive and non-immunoreactive 
nuclei are circled in black (scale bar = 100μm). One biological and one technical replicate was 
used. 
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4.9 There is nuclear Wt1 immunoreactivity in late-stage DMD human 
skeletal muscle, where the tissue has been replaced primarily by 
fibrosis and adipose tissue 
In order to determine whether these results applied to human cases of DMD, Wt1 
expression and tissue collagen deposition in healthy human muscle and highly fibrotic human 
DMD muscle was examined. Wt1 immunoreactivity was not detected in the healthy human 
muscle, but was detected in nuclei in the highly fibrotic human DMD muscle (Fig. 24A-D). At 
this advanced stage, most of the tissue had been replaced by fibrosis and adipose tissue. 
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Figure 24. Wt1 immunoreactivity is present in late-stage DMD human skeletal muscle, 
where the muscle has been replaced primarily by fibrotic and adipose tissues. 
Representative images of Wt1 immunostained human skeletal muscle, in highly fibrotic human 
DMD tissue (A), and in healthy tissue (B). In the bottom left corner, a section of magnified 
nuclei are provided for examination. Additionally, representative images of Masson’s trichrome 
stained human skeletal muscle, in highly fibrotic human DMD tissue (C), and in healthy tissue 
(D) (scale bar = 100μm). One biological and one technical replicate was used. 
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5  DISCUSSION 
 
5.1 Summary 
Adequate treatment of Duchenne muscular dystrophy (DMD) and other muscular 
dystrophies is often impeded due to extensive muscle fibrosis throughout the body, reducing the 
ability of therapeutic agents to penetrate affected tissues. It is therefore a high priority to 
determine biomarkers for pre-fibrotic and early fibrotic states, as well as therapy candidates to 
reduce fibrosis. Wt1 is a protein which can potentially address both of these issues, having been 
linked to fibrosis in idiopathic pulmonary fibrosis, and DD179,181.  This has led to the hypothesis 
that Wt1 immunoreactivity is a marker for fibrosis in a mouse model of DMD. The specific aims 
of this study, to address this hypothesis, were to evaluate the timing and location of expression of 
Wt1 with respect to the onset of fibrosis in a mouse model of DMD, and to determine which 
isoforms of Wt1 are altered during the onset of fibrosis. 
This study has produced several major results concerning Wt1 expression in DMD. 
Firstly, it demonstrated that the proportion of Wt1 immunoreactive nuclei is increased prior to 
and during the onset of fibrosis in the diaphragm and gastrocnemius skeletal muscles. Secondly, 
it showed that the proportion of Wt1 immunoreactive nuclei, following a period of increase, 
returns to wildtype levels after the onset of skeletal muscle fibrosis. Thirdly, it showed that 
proportion of Wt1 immunoreactive nuclei does not change in Mdx, Mdx/Utrn+/-, or Mdx/Utrn-/- 
heart tissue, but that it is nonetheless expressed in these tissues, possibly indicative of some roles 
in the maintenance of these tissues. Thirdly, it indicated that neither in the gastrocnemius, 
diaphragm, or heart, are there significant changes in Wt1 immunoreactivity in the muscle 
cytoplasm or non-muscle tissue. Additionally, it provided initial evidence that Wt1 mRNA 
upregulation may coincide with the increase in proportion of Wt1 immunoreactive nuclei, but 
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that there is no change in ratio of major Wt1 isoforms. Furthermore, it indicated that nuclear Wt1 
immunoreactivity takes place in developing myotubes, in addition to possibly fibrogenic cells or 
cells present in inflammatory infiltrate. Finally, it demonstrated that there is nuclear Wt1 
immunoreactivity in fibrosis produced by DMD in human patient muscle.  
5.2 Implications of Experimental Findings 
5.2.1 Proportion of Wt1 immunoreactive nuclei is increased prior to and 
during early collagen deposition in mouse skeletal muscle, but not 
during late collagen deposition 
In order to begin addressing the timing and location of Wt1 immunoreactivity with 
respect to the onset of fibrosis, the proportion of Wt1 immunoreactive nuclei, and collagen 
deposition, were evaluated in skeletal muscle.  
Aside from the Mdx gastrocnemius, the disease model skeletal muscles examined all 
expressed a significantly increased proportion of Wt1 immunoreactive nuclei relative to the age-
matched wildtype at some timepoint. Either simultaneously, or at an older timepoint, these 
tissues also showed significant collagen deposition relative to the age-matched wildtype (Fig. 11, 
15, 19). This is the first study to indicate the expression of Wt1 in a disease model of DMD. Wt1 
is a complex protein with conflicting past research suggesting it may both promote and inhibit 
fibrosis. Much of this prior body of work has focused primarily on its contribution to lung 
fibrosis. One such study by Sontake and colleagues found that Wt1 was upregulated in 
mesenchymal and mesothelial cells in idiopathic pulmonary fibrosis. Transduction of human 
fibroblasts with lentivirus containing Wt1 was shown to increase expression of a major 
myofibroblast marker, α-SMA, and its knockdown with siRNA was shown to decrease it. This 
knockdown additionally downregulated many transcripts associated with extracellular matrix 
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production, including integrin 7 (Itg7), integrin 2 (Itg2), and collagen 4 (Col14)180. In contrast to 
this, a 2014 study investigating pleural mesothelial cell plasticity suggested that Wt1 serves a 
role in preventing conversion of cells into a myofibroblast phenotype. Loss of Wt1, through short 
hairpin knockdown, was shown to promote this transformation, and actually led to an increase in 
α-SMA expression181. Past research by the O’Gorman lab examining fibrosis in DD patients 
indicated that Wt1 is expressed in fibrotic palmar fascia of the hand in DD patients. This was 
shown through both qPCR and immunohistochemical staining. However, no difference in Wt1 
expression compared to the control, either through qPCR or through immunohistochemical 
staining, was found in palmar fascia of DD patients which had not already become fibrotic182. In 
order to acquire an adequate understanding of Wt1, these conflicts will need to be resolved. In 
the context of this literature, this study’s results agree with those of the Sontake and O’Gorman 
groups, that the expression of Wt1 is increased in association with fibrosis.  
In several of the tissues examined, such as the Mdx and Mdx/Utrn+/- diaphragm, and the 
Mdx/Utrn-/- gastrocnemius, the increase in proportion of Wt1 immunoreactive nuclei occurred in 
the absence of a significant increase in collagen deposition. The significant increase in collagen 
deposition was only detected, instead, at a later timepoint. This contrasts the results from the 
O’Gorman lab, as the non-fibrotic palmar fascia of DD patients which had not already become 
fibrotic showed no increase in nuclear Wt1 immunoreactivity182. This may speak to the 
differences in Wt1 expression in the fibrosis of different tissues, or it may indicate that nuclear 
Wt1 immunoreactivity is increased only immediately antecedent to fibrosis. The syngeneic 
tissues evaluated in the O’Gorman study may not have yet reached this antecedent point, or were 
not to become fibrotic at all. Nevertheless, the results of this study indicate that the proportion of 
Wt1 immunoreactive nuclei may be increased by pre-fibrotic conditions that persist into the early 
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stages of fibrosis. These may be the same conditions which prompt fibrosis itself, but additional 
research would be required before this could be confirmed.   
Of all the disease models analyzed, the only skeletal muscle which did not show a 
significant increase in the proportion of Wt1 immunoreactive nuclei, or a significant increase in 
collagen deposition, was the Mdx gastrocnemius. The differences in proportion of Wt1 
immunoreactive nuclei and collagen deposition between diaphragm and gastrocnemius muscle in 
the Mdx model may be explained through differences in progression of fibrosis. This may 
additionally elucidate the differences between the Mdx gastrocnemius muscle and the other 
disease models’ examined skeletal muscles. The Mdx mouse model does not perfectly 
recapitulate the pathology of DMD as seen in humans. Instead, it experiences lower rates of limb 
fibrosis, as the presence of utrophin within this model is suggested to ameliorate muscle cell 
death186–188. Past work in the Hoffman lab has indicated that the 10 month old Mdx diaphragm 
(Fig. 17E), but not the Mdx gastrocnemius (Fig. 17D), becomes fibrotic. This past work has also 
found that both skeletal muscles have similar rates of regeneration as quantified by the percent of 
centrally-nucleated myofibers. This would suggest that it is fibrosis, and not muscle 
regeneration, which is triggering this increase in proportion of Wt1 immunoreactive nuclei194. 
Established literature exists describing the expression of Wt1 in developing, though not 
regenerating, skeletal muscle. There is immunohistochemical evidence for Wt1 being 
upregulated in the cytoplasm of muscle cells during development. However, an absence of 
nuclear Wt1 expression was also found in these studies, which would appear to contradict the 
nuclear immunoreactivity pattern in this study200. Other past research does show the presence of 
nuclear Wt1 in developing skeletal muscle, though does not describe its presence in regenerating 
81 
 
 
 
muscle201. It may the case that some form of cross-talk occurs where regenerating skeletal 
muscle expresses Wt1 only in the presence of the pre-fibrotic, or early fibrotic, environment.  
The return in proportion of Wt1 immunoreactive nuclei to levels similar to the wildtype 
in the 10-14 month old skeletal muscle during late collagen deposition is a novel finding (Fig. 
19A-B). This supports, though does not confirm, its role as a protein expressed in advance of 
fibrosis. Were the proportion of Wt1 immunoreactive nuclei increased as a result of fibrosis, it 
would consistently occur regardless of the time after fibrosis onset. This would suggest that it is 
the early fibrotic environment which promotes, or at least tolerates, nuclear Wt1 
immunoreactivity. The proportion of Wt1 immunoreactive nuclei may be reduced once the 
fibroblast population ceases to divide and enters quiescence181. Another possibility is that the 
nuclear Wt1 immunoreactivity that took place in developing myotubes may no longer be visible, 
as the regenerative capacity of the muscle tissue is exhausted, but this seems unlikely due to the 
presence of developing myotubes at the 10-14 month timepoint. 
5.2.2 Proportion of Wt1 immunoreactive nuclei does not change in Mdx, 
Mdx/Utrn+/-, or Mdx/Utrn-/- heart tissue 
Beyond skeletal muscle, it was also important to evaluate the timing and location of 
changes in the proportion of Wt1 immunoreactive nuclei with respect to the onset of fibrosis in 
cardiac muscle. Quantification of collagen deposition in the heart showed surprising results, with 
none of the cohorts showing a statistically significant difference in collagen deposition compared 
to their age-matched wildtype controls (Fig. 11C, 15C, 19C). Earlier data on 4-5 week old and 8-
10 week old heart collagen deposition corresponded well with the literature, but past studies 
evaluating the hearts of aged Mdx and Mdx/Utrn+/- mice have indicated that beyond ten months, 
the organ is fibrotic202,203. The small sample size and increased age range utilized in this study 
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may be one possible explanation for this, as the average collagen deposition present in the 10-14 
month old Mdx and Mdx/Utrn+/- hearts was still higher than that of the 10-14 month old 
wildtype hearts. The lack of a statistically significant increase in proportion of Wt1 
immunoreactive nuclei in 8-10 week old Mdx/Utrn-/- mice hearts furthermore compounds this 
issue. This absence is peculiar, as previous work has suggested that as early as 16 weeks of age, 
Mdx/Utrn-/- hearts are fibrotic204. As collagen deposition and the proportion of Wt1 
immunoreactive nuclei in both ventricles was evaluated as part of this study, and past work 
primarily evaluated left ventricle fibrosis, it may be pertinent to evaluate the proportion of Wt1 
immunoreactive nuclei and its relationship to fibrosis in this component of the heart alone. 
An alternative explanation for the differences in proportion of Wt1 immunoreactive 
nuclei when compared to the skeletal muscle is that there appears to be a higher, though not 
significantly so, basal level of nuclear Wt1 immunoreactivity in the heart than in either skeletal 
muscles analyzed. This may mask slight changes in the proportion of Wt1 immunoreactive 
nuclei which arise as a result of fibrosis initiation. The existing literature supports Wt1 
upregulation in the heart following myocardial infarction and ensuing hypoxia. Primarily, this is 
through Wt1’s roles in managing the proliferation of coronary vascular cells148,157,163,205. This 
study’s results, however, show high basal nuclear Wt1 immunoreactivity even in the wildtype, 
which may be indicative of other unknown roles Wt1 may be playing in adult cardiac muscle. To 
address the issue of statistical power with this particular outcome, it will be necessary to explore 
Wt1’s role in the heart to a greater extent in the future. 
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5.2.3 Wt1 immunoreactivity patterns in muscle cytoplasm and non-
muscle tissue do not change in mouse skeletal and cardiac muscle, 
and are not significantly different from an absence of expression 
Although Wt1’s principal role is often thought to be in the nucleus, it is important 
nonetheless to also consider its possible roles in the muscle cytoplasm and non-muscle tissue. 
With regards to Wt1 immunoreactivity in the skeletal muscle cytoplasm, results indicated no 
significant differences in the area positive for Wt1 in any of the disease models compared to the 
age-matched wildtype control (Appendix K). In many of the tissues examined, the presence of 
Wt1 in the muscle cytoplasm and non-muscle tissue were low enough that they were 
indistinguishable from the signal in the negative control (Appendix B-D). None of the other 
tissues compared showed significant difference from tissues where this was the case.  
Wt1 has previously been identified to be expressed in the cytoplasm in other muscle 
groups. Expression of Wt1 is linked to skeletal muscle development, so its elevation earlier in 
development would be in accordance with established literature177. One possibility is that the 
antibody used in this study may not necessarily target all isoforms of Wt1, and that those 
isoforms which localize to the cytoplasm are not among the ones targeted. Alternatively, Wt1 
expression may be low enough that only when a significant amount of the protein localizes to a 
relatively small location, such as the nucleus, is the immunohistochemical system that was 
utilized sensitive enough to pick it up.  
Turning attention to Wt1 immunoreactivity in the cardiac muscle cytoplasm, results 
indicated, similar to the skeletal muscle, that there were no significant differences in the area 
positive for Wt1 in any of the disease model tissue compared to the age-matched wildtype 
control (Appendix K). Wt1 has been shown to be associated with early cardiac development. 
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Particularly, it plays roles in vascular cell proliferation, and its knockout causes reduced 
coronary vascularization, as well as epicardial thinning and smaller ventricles152. As little cardiac 
damage was observed in the models utilized, it may be possible that a more severely affected 
model, such as an older Mdx/Utrn-/- or Mdx/Utrn+/- model, may have Wt1 signal in the muscle 
cytoplasm of the heart. With increased cardiac injury, Wt1 expression may be more greatly 
promoted so as to prompt vascularization.  
The absence of any change in percent immunoreactivity for Wt1 in the non-muscle tissue 
seems to conflict with prior observations in DD patients182. However, it may be the case that the 
possible Wt1 upregulation found in DMD tissues is not high enough, is not of the proper 
isoforms, or is not in the proper cell types, that it would appear in non-muscle tissues.   
5.2.4 Proportion of Wt1 immunoreactive nuclei and collagen deposition 
patterns show weak respective trends over time toward decreasing 
and increasing in skeletal muscle  
As it had been determined that proportion of Wt1 immunoreactive nuclei and collagen 
deposition varied compared to the wildtype in several of the disease models, it became 
worthwhile to examine if Wt1 immunoreactivity and collagen deposition formed any pattern 
over time. Proportion of Wt1 immunoreactive nuclei in skeletal muscle showed a weak trend 
toward decreasing over time, with several earlier timepoints showing significantly greater signal 
than later timepoints. In contrast, tissue collagen deposition showed a weak trend toward 
increasing over time, with several earlier timepoints showing a significantly lower signal than 
later timepoints (Fig. 20). This may speak to Wt1’s roles in early disease progression, and 
potentially cell proliferation. As an organism ages, the number of cells which actively divide, or 
which begin to divide when stimulated by inflammation, may be reduced181. If it is the case that 
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these cells are the ones expressing Wt1, then it would be reasonable to see this reduction with 
time. The increase in collagen deposition with time seems to occur solely for the disease models, 
and is likely representative of the gradual production of collagen.  
However, it should be noted that for both proportion of Wt1 immunoreactive nuclei and 
collagen deposition, these observed patterns were weak. Although there was never a case of a 
later timepoint showing lower collagen deposition, or greater Wt1 expression, there were many 
cases where a significant difference was not found whatsoever. This speaks to the need for 
additional power when conducting an analysis in this fashion, as well as the importance of 
putting the tissue signal in the context of the age-matched wildtype control.    
5.2.5 Total Wt1 mRNA is upregulated during early collagen deposition 
in mouse skeletal muscle without a change in the ratios of its major 
isoforms. 
To explore which of the different isoforms of Wt1 were being upregulated, as well as 
changes in total Wt1 expression, both of these measures were evaluated through qPCR. An 
approximately 6-fold upregulation in total Wt1 mRNA in the Mdx/Utrn+/- model gastrocnemius 
muscle at 8-10 weeks of age was identified. This corresponds well with past literature evaluating 
other forms of fibrosis (Fig. 22C)182.  
Examination of whether the four major isoforms of Wt1 changed in ratio showed no 
significant differences between the 8-10 week old wildtype and Mdx/Utrn+/- models (Fig. 22D). 
As mentioned previously, Wt1 has numerous isoforms with multiple distinct roles, largely 
divisible into four major groups. Its roles envelope transcriptional regulation, post-transcriptional 
modification, and the binding of other proteins, giving it a wide range of means to enact its 
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function. The role Wt1 plays in fibrosis may be mediated by only a single isoform of the protein. 
However, these results suggest that either the upregulation of Wt1 that is associated with fibrosis 
is across all variants of the protein or that an isoform, distinct from the four major forms, is being 
upregulated.  
Another interesting result of note is that the observed ratio of the isoforms, for A, B, C, 
and D, was 0.32:0.19:0.27:0.22. This is in contrast to past research studying Wt1 isoforms in 
certain forms of cancer, and may reflect changes of the isoform ratios between different 
tissues199.  
5.2.6 Nuclear Wt1 immunoreactivity in mouse skeletal muscle during 
early collagen deposition is also present in myotubes 
Nuclear Wt1 immunoreactivity in developing myotubes was also noted, identified 
through the central positions of the nuclei, both in tissues which showed (Fig. 23A) and did not 
show (Fig. 23B) significant increases in proportion of Wt1 immunoreactive nuclei overall. This 
provides evidence that the muscle is recapitulating part of development during the regeneration 
process, as Wt1 immunoreactivity has previously been seen to be upregulated during early 
skeletal muscle development. However, this upregulation in past investigations has been subject 
to some debate. Studies on the topic disagree on whether Wt1 is expressed primarily in the 
cytoplasm or the nuclei of developing muscle tissues200,201. It may be that with the recapitulation 
of development during the regeneration process, there is increased overall expression of Wt1. 
This may promote not only cytoplasmic Wt1, but also nuclear Wt1, resulting in increased nuclear 
Wt1 signal in skeletal muscle. The absence of a significant increase in proportion of Wt1 
immunoreactive nuclei in the Mdx gastrocnemius, despite its undergoing muscle regeneration, 
further complicates this issue. This may play back into the possibility of cross-talk where 
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regenerating skeletal muscle expresses Wt1 only in the pre-fibrotic, or early fibrotic, 
environment. 
However, not all of the nuclear Wt1 immunoreactivity detected was found in skeletal 
muscle, as a significant portion was also present in areas of inflammatory infiltrate (Fig. 10J, 
15E). Although this may be possible fibroblast expression of Wt1, there are other potential cell 
candidates in these regions. These include mast cells, neutrophils, basophils, eosinophils, 
macrophages, and lymphocytes. These areas of inflammation may, furthermore, be the arrival 
site of fibrocytes, and the location where pericytes migrate to after beginning their transition into 
myofibroblasts55,206. One cell type of interest in this location that may be Wt1 positive are 
lymphocytes.  A 2006 study showed that Wt1 was expressed in adult human lymphocytes, but 
additionally indicated that neither monocytes nor granulocytes express the protein207. There are, 
additionally, Wt1 positive cells on the periphery of myofibers (Fig. 10, 14). This expression may 
instead be endogenous fibroblasts, FAP cells, or satellite muscle cells, which are exiting 
quiescence and either beginning to divide, differentiate, or participate in the inflammatory and 
fibrotic processes.   
5.2.7 There is nuclear Wt1 immunoreactivity in late-stage DMD human 
skeletal muscle, where the muscle has been replaced primarily by 
fibrotic and adipose tissues 
In order to determine how well the results found carried over from the mouse model to 
human subjects, highly fibrotic DMD patient muscle tissue and non-fibrotic human muscle tissue 
were evaluated for Wt1 immunoreactivity. While immunoreactivity in the highly fibrotic human 
DMD patient muscle tissue was found, no immunoreactivity was found in the non-fibrotic tissue 
(Fig. 24). This contrasts the results in the mouse model in this study, which would indicate that 
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immunoreactivity in humans should become absent toward the peak of fibrosis. A greater 
replicative capacity in human fibroblasts, or a greater resistance to initial muscle death, may be 
possible explanations, though this would require additional human samples for statistical power. 
5.3 Limitations 
There are some limitations associated with this project which will need to be resolved in 
future experiments. Several of these issues concern immunohistochemical work. The 
immunohistochemistry performed to detect the presence of Wt1 is problematic in that the 
fibrogenic process is inherently heterogeneous throughout muscle tissue, with particular sections 
of the tissue becoming fibrotic long before others55. Some parts of the tissue may never become 
fibrotic. For this reason, only in regions of the tissue where fibrosis begins, or will begin, can 
expression of Wt1 be expected. This may lead to an inaccurate assessment of Wt1 expression 
across the entire tissue, should an appropriate proportion of fibrotic regions not be captured 
during sectioning. Addressing this may necessitate additional immunohistochemical staining, or 
alternative whole-tissue based analyses, such as western blotting. The antibody used for this 
evaluation was a rabbit monoclonal antibody against the 50-250 amino acids of the Wt1 protein. 
This may introduce some uncertainty, as well. The isoforms adopted by the protein may not 
necessarily still maintain the epitope for this antibody to bind to, so particular forms of Wt1 may 
be undetected by this antibody. This may be a possible explanation for why the heart showed no 
significant differences in Wt1 positivity in the affected tissues, if the Wt1 isoform which 
increased in expression in the heart was not one to which the antibody bound. Furthermore, this 
may explain why the overall Wt1 positivity in the diaphragm tended to be higher than that of the 
gastrocnemius. The isoforms that the antibody detects may not be as highly expressed in the 
gastrocnemius, compared to the diaphragm. A possible solution to the antibody issue may be 
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through using a polyclonal antibody against the whole Wt1 protein, though this would introduce 
potential off-targeting effects. An additional issue with the immunohistochemistry performed is 
that it takes the form of DAB staining, which is only semi-quantitative. The absorbance of light 
by oxidized DAB is not linear with respect to the quantity of DAB present. Therefore, 
quantification of total DAB stain intensity is not a direct measure for Wt1 expression, and 
instead it is only possible to identify whether particular nuclei are positive for Wt1, or whether a 
region is positive for Wt1. This can introduce uncertainty regarding whether Wt1 is being 
upregulated, as it may be the case that it is merely being localized to the nucleus or cytoplasm 
instead. This is in contrast with fluorescent immunohistochemistry, where the fluorescent signal 
is proportional to the number of fluorophores bound to the protein of interest. A fluorescent 
signal produced in this fashion is representative of the total amount of that protein present. 
Unfortunately, for proteins which are expressed in very small quantities, such as transcription 
factors like Wt1, fluorescent techniques may not be strong enough to resolve the protein. Thus, 
chromogenic reporters such as DAB must be used, as in the case of this study. Western blotting 
may be a potential supplementary technique to address this in the future. Finally, as Wt1 was 
identified in cell types besides only what were apparently fibroblasts, we cannot say for certain 
that the proportion of Wt1 immunoreactive nuclei was increased in fibroblasts. It may be the case 
that this increase was exclusively limited to non-fibroblast cell types. In order to address this in 
the future, co-staining for other markers of fibroblasts would be required.  
Regarding limitations concerning Masson’s trichrome staining, other literature identifies 
10-14 month old Mdx and Mdx/Utrn+/- heart tissue as being fibrotic, while the results produced 
by this study indicated otherwise202,203. This is possibly explained through the increased age 
range and smaller sample size used in this study. The variation introduced by these factors may 
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be enough to make the differences between 10-14 month old Mdx and Mdx/Utrn+/- heart tissue 
and 10-14 month old wildtype heart tissue insignificant. Addressing this limitation would require 
additional samples of aged tissue in order to determine if the 10-14 month old heart tissue is 
fibrotic.  
Concerning additional limitations regarding the heart, it may be the case that the basal 
Wt1 expression is high enough as to mask increases in Wt1 expression in the disease models. 
Fortunately, much as is the case with the Masson’s trichrome staining, addressing this limitation 
would involve utilizing additional samples of heart in these age ranges. This would be able to 
identify whether or not there are significant differences in Wt1 immunoreactivity between these 
ages and genotypes. 
Finally, regarding limitations in qPCR, there are some issues with respect to quantifying 
the total amount of each Wt1 isoform. Although the inclusion of exon 5 and the KTS sequence 
are often considered the major features which differentiate isoforms, these are not the only 
features which can differ among isoforms. Wt1 has multiple start sites for translation, capable of 
producing isoforms of different lengths. This may play a role in altering the ultimate function of 
the protein208. In order to address this issue, designing primers which are capable of reliably 
performing qPCR on the differing Wt1 isoforms will be a priority in the future.  
5.4 Future Directions 
With regards to future research, the next experiments to perform to expand on this 
project, besides those listed in the previous section, can take several forms. The evidence of 
substantial inflammatory infiltrate suggests that exploring immune cells, such as macrophages 
and lymphocytes, may be one possible future path to pursue. These cells may become Wt1 
positive either as a result of expressing Wt1 themselves or phagocytosing it. Secondary 
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infiltration of immune cells which have phagocytosed Wt1 and then travelled into a nearby 
lymph node may provide a unique diagnostic tool, as sampling of lymph node fluid for Wt1 
positive immune cells would allow detection of fibrotic tissue downstream of the node. Western 
blots can be performed to analyze differences in Wt1 level in the diaphragm as well as in the 
gastrocnemius muscle. This would provide definitive evidence regarding in which genotypes and 
age groups Wt1 is upregulated. Expanding the qPCR exploration to include variants of Wt1 
mRNA that begin at different start sites may also be a future direction. Rather than analyze all 
Wt1 isoforms, however, it may be beneficial to evaluate the Wt1 isoforms that begin at different 
start sites independently of those created through the selective inclusion of exon five and the 
KTS sequence. Another possible experiment is fluorescence activated cell sorting, followed by 
western blots, in order to separate out different cell types and quantify differences in Wt1 
expression within them. This could target cells such as developing myotubes, fibroblasts, or 
immune cells. RNAseq is also a possible follow-up to fluorescence activated cell sorting, as it 
would allow determination of differences in mRNA variant regulation in fibroblasts, and allow 
us to determine which mRNAs are upregulated or downregulated in response to, or alongside, 
Wt1 upregulation. Examining different ages of tissues through this method would allow us to 
determine which Wt1 isoforms are upregulated at the start and end of fibrosis, and determine if 
any isoforms remain upregulated following the broad downregulation at 10-14 months of age. A 
final experiment to pursue, prior to trials using Wt1 immunotherapy in Mdx, Mdx/Utrn+/-, and 
Mdx/Utrn-/- mice, is the creation of conditional knockout mice. This involves the crossing of 
Wt1 conditional knockout mice with Mdx, Mdx/Utrn+/-, or Mdx/Utrn-/- mice, in order to produce 
a murine model which can be used to simulate Wt1 inhibition by an external method. Following 
induction of Wt1 knockout, these mice can be evaluated for performance in muscle strength and 
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endurance tests. Furthermore, they can be sacrificed such that their muscle tissue can be 
examined for fibrosis compared to the wildtype control and mice which do not have Wt1 
knocked out. Expanding on this, specifying this conditional knockout exclusively to fibroblasts 
may be beneficial in elucidating the function of Wt1 in fibrogenesis, but would require that 
future therapies also be fibroblast-specific. A number of existing therapies which downregulate 
Wt1 in cancers, such as Wt1 peptide vaccines and anti-Wt1 immunotherapies, may still be 
potentially used in treatments for fibrosis209,210. That Wt1 was shown to be upregulated in this 
model of fibrosis bodes well for this, as targeting Wt1 for downregulation may serve as a general 
therapy for fibrosis, as opposed to one for several specific fibrosis forms.  
5.5 Significance 
Significance for this research can be found primarily in how an understanding of fibrosis 
may benefit a number of novel and existing therapies for DMD. Existing therapies are largely 
palliative, intended to reduce symptoms of DMD. At the least, being able to determine when 
fibrosis is occurring will allow rapid treatment in order to delay the onset of symptoms and 
guarantee a higher quality of life. This supports early corticosteroid use when the 
microvasculature of the muscle is not damaged due to excessive buildup of extracellular matrix, 
allowing better perfusion of the tissue. If the case is that Wt1, or other proteins, may act as a 
marker for skeletal muscle fibrosis, but not cardiac fibrosis, then treatments can be refined to 
explicitly target those muscle groups undergoing fibrosis. Corticosteroids and physical therapy 
can be employed solely to affect those regions which are at highest risk of progressing to true 
fibrosis. This will reduce strain on the health care system, as it will no longer need to contribute 
resources to target many muscle groups simultaneously. Furthermore, this will reduce the need 
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for high corticosteroid use, moderating side effects such as weight gain and Cushingoid 
symptoms9.  
In terms of novel therapies, there are several techniques which may benefit from this 
research. As mentioned previously, viral vector strategies normally make use of recombinant 
adeno-associated viral vectors which carry components of the DMD gene, and have been shown 
to be able to restore dystrophin expression in mouse models. Challenges in delivery due to tissue 
fibrosis may be alleviated by identifying tissues which will become fibrotic early on in this 
process, allowing treatment before these difficulties arise. Other strategies involving delivery of 
key components, such as CRISPR/Cas9 delivery, may also appreciate accurate identification of 
fibrotic and pre-fibrotic regions121. Stem cell therapy is another exciting domain in which fibrosis 
detection may find substantial use. Myogenic stem cells from donors suffer from immune 
responses which limit their applicability, whereas autologous stem cells do not cause immune 
responses. Chimeraplasty and small fragment homologous replacement therapy, forms of ex vivo 
gene correction technique, can be used in autologous colonies to correct the dystrophin gene. 
Transplantation without an immune response then becomes possible, but low numbers of 
myogenic stem cells present in dystrophic muscle makes this process a challenge121,130,131. 
Through examination of biomarkers predictive of muscle fibrosis, myogenic stem cells can be 
harvested early on, allowing for circumvention of this issue entirely7. It is clear that an 
understanding of fibrosis, including its biomarkers, has innumerable benefits for health care, not 
just for DMD patients, but for all patients with progressive fibrotic conditions.  
5.6 Conclusions 
In conclusion, the hypothesis that Wt1 immunoreactivity is a marker for fibrosis in a 
mouse model of DMD was supported. The results obtained suggest that Wt1 levels do increase 
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prior to onset of fibrosis in the gastrocnemius and diaphragm muscles of a DMD mouse model. It 
is clear that the mechanisms regulating Wt1 expression are complex, and future research will be 
needed to understand them in full. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
 
 
REFERENCES 
 
1. Moat, S. J., Bradley, D. M., Salmon, R., Clarke, A. & Hartley, L. Newborn bloodspot 
screening for Duchenne muscular dystrophy: 21 years experience in Wales. Eur. J. Hum. 
Genet. 21, 1049–1053 (2013). 
2. Darras, B. T. Neuromuscular disorders of infancy, childhood, and adolescence: A 
clinician’s approach. (Elsevier/Academic Press., 2015). 
3. Ciafaloni MD, E. et al. Delayed Diagnosis in Duchenne Muscular Dystrophy: Data from 
the Muscular Dystrophy Surveillance, Tracking, and Research Network. J. Pediatr. 155, 
380–385 (2009). 
4. Mercuri, E. & Muntoni, F. Muscular dystrophies. Lancet 381, 845–860 (2013). 
5. Eagle, M. et al. Managing Duchenne muscular dystrophy - the additive effect of spinal 
surgery and home nocturnal ventilation in improving survival. Neuromuscul. Disord. 17, 
470–475 (2007). 
6. Eagle, M. et al. Survival in Duchenne muscular dystrophy: improvements in life 
expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul. 
Disord. 12, 926–929 (2002). 
7. Yiu, E. M. & Kornberg, A. J. Duchenne muscular dystrophy. J. Paediatr. Child Health 51, 
759–764 (2015). 
8. Bach, J. & Martinez, D. Duchenne muscular dystrophy: continuous noninvasive 
ventilatory support prolongs survival. Respir. Care 56, 744–750 (2011). 
9. Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: 
Diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77–93 
(2010). 
10. Bernardini, C. Duchenne Muscular Dystrophy: Methods and Protocols. 1687, (Springer 
New York, 2018). 
11. Griggs, R. C., Mendell, J. R. & Miller, R. G. Evaluation and Treatment of Myopathies. 44, 
(F.A. Davis, 1995). 
12. Hsu, J. D. The natural history of spine curvature progression in the nonambulatory 
Duchenne muscular dystrophy patient. Spine (Phila. Pa. 1976). 8, 771–775 (1983). 
13. Choi, Y.-A., Chun, S.-M., Kim, Y. & Shin, H.-I. Lower extremity joint contracture 
according to ambulatory status in children with Duchenne muscular dystrophy. BMC 
Musculoskelet. Disord. 19, 286–287 (2018). 
14. Suresh, S., Wales, P., Dakin, C., Harris, M. & Cooper, D. M. Sleep‐related breathing 
disorder in Duchenne muscular dystrophy: Disease spectrum in the paediatric population. 
J. Paediatr. Child Health 41, 500–503 (2005). 
15. Nigro, G., Comi, L. I., Politano, L. & Ban, R. J. I. The incidence and evolution of 
cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 26, 271–277 (1990). 
16. Hoogerwaard, E. et al. Signs and symptoms of Duchenne muscular dystrophy and Becker 
muscular dystrophy among carriers in the Netherlands: a cohort study. Lancet 353, 2116–
2119 (1999). 
17. Hoogerwaard, E. M. et al. Cardiac involvement in carriers of Duchenne and Becker 
muscular dystrophy. Neuromuscul. Disord. 9, 347–351 (1999). 
18. Brooke, M. H. et al. Clinical investigation in Duchenne dystrophy: II. Determination of 
the ‘power’ of therapeutic trials based on the natural history. Muscle and Nerve 6, 91–103 
96 
 
 
 
(1983). 
19. Laing, N. G., Davis, M. R., Bayley, K., Fletcher, S. & Wilton, S. D. Molecular diagnosis 
of Duchenne muscular dystrophy: past, present and future in relation to implementing 
therapies. Clin. Biochem. Rev. 32, 129 (2011). 
20. Worton, R. G. & Thompson, M. W. Genetics of Duchenne Muscular Dystrophy. Annu. 
Rev. Genet. 22, 601–629 (1988). 
21. Belfall, B. et al. The Duchenne muscular dystrophy gene product is localized in 
sarcolemma of human skeletal muscle. Nature 333, 466–469 (1988). 
22. Hoffman, E. P. et al. Characterization of Dystrophin in Muscle-Biopsy Specimens from 
Patients with Duchenne’s or Becker’s Muscular Dystrophy. N. Engl. J. Med. 318, 1363–
1368 (1988). 
23. Aartsma-Rus, A., Van Deutekom, J. C., Fokkema, I. F., Van Ommen, G. B. & Den 
Dunnen, J. T. Entries in the Leiden Duchenne muscular dystrophy mutation database: An 
overview of mutation types and paradoxical cases that confirm the reading‐frame rule. 
Muscle and Nerve 34, 135–144 (2006). 
24. Blake, D. J., Weir, A., Newey, S. E. & Davies, K. E. Function and genetics of dystrophin 
and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291–329 (2002). 
25. Abbs, S. et al. Best Practice Guidelines on molecular diagnostics in Duchenne/Becker 
muscular dystrophies . Neuromuscular Disorders  20, 422–427 (2010). 
26. Clerk, A., Strong, P. N. & Sewry, C. A. Characterisation of dystrophin during 
development of human skeletal muscle . Development  114, 395 (1992). 
27. Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: one gene, several 
proteins, multiple phenotypes. Lancet Neurology 2, 731–740 (2003). 
28. Flanigan, K. M. et al. Nonsense mutation‐associated Becker muscular dystrophy: interplay 
between exon definition and splicing regulatory elements within the DMD gene. Hum. 
Mutat. 32, 299–308 (2011). 
29. Flanigan, K. M. et al. Mutational spectrum of DMD mutations in dystrophinopathy 
patients: application of modern diagnostic techniques to a large cohort. Hum. Mutat. 30, 
1657–1666 (2009). 
30. Tuffery-Giraud, S. et al. Genotype-phenotype analysis in 2,405 patients with a 
dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. 
Hum. Mutat. 30, 934–945 (2009). 
31. Gao, Q. & McNally, E. M. The Dystrophin Complex: structure, function and implications 
for therapy. Compr. Physiol. 5, 1223–1239 (2015). 
32. Bushby, K. M. D. & Gardner-Medwin, D. The clinical, genetic and dystrophin 
characteristics of Becker muscular dystrophy: I. Natural history. J. Neurol. 240, 98–104 
(1993). 
33. Hoffman, E. P. & Dressman, D. Molecular pathophysiology and targeted therapeutics for 
muscular dystrophy. Trends Pharmacol. Sci. 22, 465–470 (2001). 
34. Campbell, K. P. et al. Primary structure of dystrophin-associated glycoproteins linking 
dystrophin to the extracellular matrix. Nature 355, 696–702 (1992). 
35. Yoshida, M. et al. Biochemical evidence for association of dystrobrevin with the 
sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum. 
Mol. Genet. 9, 1033–1040 (2000). 
36. Miller, G., Wang, E. L., Nassar, K. L., Peter, A. K. & Crosbie, R. H. Structural and 
functional analysis of the sarcoglycan–sarcospan subcomplex. Exp. Cell Res. 313, 639–
97 
 
 
 
651 (2007). 
37. Braun, R., Wang, Z., Mack, D. & Childers, M. Gene therapy for inherited muscle 
diseases: where genetics meets rehabilitation medicine. Am. J. Phys. Med. Rehabil. 93, 
97–107 (2014). 
38. Williamson, R. A. et al. Dystroglycan is essential for early embryonic development: 
disruption of Reichert’s membrane in Dag1-null mice. Hum. Mol. Genet. 6, 831–841 
(1997). 
39. Belanto, J. J. et al. Microtubule binding distinguishes dystrophin from utrophin. Proc. 
Natl. Acad. Sci. U. S. A. 111, 5723–5728 (2014). 
40. Prins, K. W. et al. Dystrophin Is a Microtubule-Associated Protein. J. Cell Biol. 186, 363–
369 (2009). 
41. Rybakova, I. N., Patel, J. R. & Ervasti, J. M. The Dystrophin Complex Forms a 
Mechanically Strong Link between the Sarcolemma and Costameric Actin . The Journal 
of Cell Biology  150, 1209–1214 (2000). 
42. Pardo, J. V., Siliciano, J. D. & Craig, S. W. A vinculin-containing cortical lattice in 
skeletal muscle: Transverse lattice elements (“Costameres”) mark sites of attachment 
between myofibrils and sarcolemma. Proc. Natl. Acad. Sci. United States Am. 80, 1008–
1012 (1983). 
43. Danowski, B. A., Imanaka-Yoshida, K., Sanger, J. M. & Sanger, J. W. Costameres Are 
Sites of Force Transmission to the Substratum in Adult Rat Cardiomyocytes . The Journal 
of Cell Biology  118, 1411–1420 (1992). 
44. Goldspink, G. Changes in muscle mass and phenotype and the expression of autocrine and 
systemic growth factors by muscle in response to stretch and overload. J. Anat. 194, 323–
334 (1999). 
45. Deconinck, N. Pathophysiology of Duchenne muscular dystrophy: Current hypotheses. 
Pediatr. Neruology 36, 1–7 (2007). 
46. Straub, V., Rafael, J. A., Chamberlain, J. S. & Campbell, K. P. Animal Models for 
Muscular Dystrophy Show Different Patterns of Sarcolemmal Disruption . The Journal of 
Cell Biology  139, 375–385 (1997). 
47. Lapidos, K., Kakkar, R. & McNally, E. The dystrophin glycoprotein complex: signaling 
strength and integrity for the sarcolemma. Circ. Res. 94, 1023–1031 (2004). 
48. Mizuno, Y. Prevention of myonecrosis in mdx mice: Effect of immobilization by the local 
tetanus method. Brain Dev. 14, 319–322 (1992). 
49. Carafoli, E. & Molinari, M. Calpain: A protease in search of a function? Biochem. 
Biophys. Res. Commun. 247, 193–203 (1998). 
50. Brenman, J. E., Chaos, D. S., Xia, H., Aldape, K. & Bredt, D. S. Nitric oxide synthase 
complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne 
muscular dystrophy. Cell 82, 743–752 (1995). 
51. Crosbie, R. H. et al. mdx muscle pathology is independent of nNOS perturbation . Human 
molecular genetics  7, 823–829 (1998). 
52. Huang, P. L., Dawson, T. M., Bredt, D. S., Snyder, S. H. & Fishman, M. C. Targeted 
disruption of the neuronal nitric oxide synthase gene . Cell  75, 1273–1286 (1993). 
53. Thomas, G. D. Functional muscle ischemia in Duchenne and Becker muscular dystrophy. 
Frontiers in physiology 4, 381 (2013). 
54. Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199–210 
(2008). 
98 
 
 
 
55. Rockey, D., Bell, P. & Hill, J. Fibrosis - A Common Pathway to Organ Injury and Failure. 
N. Engl. J. Med. 372, 1138–1149 (2015). 
56. Remuzzi, G. & Bertani, T. Pathophysiology of Progressive Nephropathies . The New 
England Journal of Medicine  339, 1448–1456 (1998). 
57. King Prof, T. E., Pardo Prof, A. & Selman MD, M. Idiopathic pulmonary fibrosis. Lancet 
378, 1949–1961 (2011). 
58. Bataller, R. & Gao, B. Liver Fibrosis in Alcoholic Liver Disease . Seminars in Liver 
Disease  35, 146–156 (2015). 
59. Kharraz, Y., Guerra, J., Pessina, P., Serrano, A. L. & Muñoz-Cánoves, P. Understanding 
the process of fibrosis in Duchenne muscular dystrophy. Biomed Res. Int. 2014, 965611–
965631 (2014). 
60. Chronic Kidney Disease Fact Sheet. US Department of Health and Human Services, 
Centers for Disease Control and Prevention 1–4 (2017). 
61. Wynn, T. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4, 583–594 
(2004). 
62. Meng, X., Nikolic-Paterson, D. & Lan, H. Inflammatory processes in renal fibrosis. Nat. 
Rev. Nephrol. 10, 493–503 (2014). 
63. Mann, C. J. et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet. 
Muscle 1, 21 (2011). 
64. Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation 
and polarization. Trends Immunol. 25, 677–686 (2004). 
65. Murakami, S. & Okada, H. Lymphocyte-fibroblast interactions. Crit. Rev. Oral Biol. Med. 
8, 40–50 (1997). 
66. Donlin, L. T., Jayatilleke, A., Giannopoulou, E. G., Kalliolias, G. D. & Ivashkiv, L. B. 
Modulation of TNF-induced macrophage polarization by synovial fibroblasts. J. Immunol. 
193, 2373–2383 (2014). 
67. Maurer, D. H., Hanke, J. H., Mickelson, E., Rich, R. R. & Pollack, M. S. Differential 
presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated 
dermal fibroblasts. J. Immunol. 139, 715 (1987). 
68. Arnold, L. et al. Inflammatory monocytes recruited after skeletal muscle injury switch 
into antiinflammatory macrophages to support myogenesis. J. Exp. Med. 204, 1057–1069 
(2007). 
69. Hinz, B. et al. The myofibroblast: One function, multiple origins. Am. J. Pathol. 170, 
1807–1816 (2007). 
70. Lieber, R. L. & Ward, S. R. Cellular mechanisms of tissue fibrosis. 4. Structural and 
functional consequences of skeletal muscle fibrosis. Am. J. Physiol. Physiol. 305, C241–
C252 (2013). 
71. Vidal, B. et al. Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative 
macrophage activation pathway. Genes Dev. 22, 1747 (2008). 
72. Brandan, E. & Gutierrez, J. Role of proteoglycans in the regulation of the skeletal muscle 
fibrotic response. FEBS J. 280, 4109–4117 (2013). 
73. Smith, L. R. & Barton, E. R. Regulation of fibrosis in muscular dystrophy. Matrix Biol. 
68–69, 602–615 (2018). 
74. Flanders, K. C. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 85, 47–
64 (2004). 
75. Leask, A. & Abraham, D. TGF-β signaling and the fibrotic response. FASEB J. 18, 816–
99 
 
 
 
827 (2004). 
76. Le Grand, F. & Rudnicki, M. A. Skeletal muscle satellite cells and adult myogenesis. 
Curr. Opin. Cell Biol. 19, 628–633 (2007). 
77. Porter, J. D. et al. A chronic inflammatory response dominates the skeletal muscle 
molecular signature in dystrophin-deficient mdx mice. Hum. Mol. Genet. 11, 263–272 
(2002). 
78. Bell, C. D. & Conen, P. E. Histopathological changes in Duchenne muscular dystrophy. J. 
Neurol. Sci. 7, 529–544 (1968). 
79. Duance, V. C., Dunn, M., Stephens, H. R., Bailey, A. J. & Dubowitz, V. A role for 
collagen in the pathogenesis of muscular dystrophy? Nature 284, 470–472 (1980). 
80. Desguerre, I. et al. Endomysial Fibrosis in Duchenne Muscular Dystrophy: A Marker of 
Poor Outcome Associated With Macrophage Alternative Activation. J. Neuropathol. Exp. 
Neurol. 68, 762–773 (2009). 
81. Klingler, W., Jurkat-Rott, K., Lehmann-Horn, F. & Schleip, R. The role of fibrosis in 
Duchenne muscular dystrophy. Acta Myol. 31, 184 (2012). 
82. Schabort, E. J., van der Merwe, M., Loos, B., Moore, F. P. & Niesler, C. U. TGF-beta’s 
delay skeletal muscle progenitor cell differentiation in an isoform-independent manner. 
Exp. Cell Res. 315, 373 (2009). 
83. Cencetti, F. et al. TGFβ1 evokes myoblast apoptotic response via a novel signaling 
pathway involving S1P4 transactivation upstream of Rho-kinase-2 activation. FASEB J. 
27, 4532–4546 (2013). 
84. Cencetti, F., Bernacchioni, C., Nincheri, P., Donati, C. & Bruni, P. Transforming Growth 
Factor- 1 Induces Transdifferentiation of Myoblasts into Myofibroblasts via Up-
Regulation of Sphingosine Kinase-1/S1P3 Axis. Mol. Biol. Cell 21, 1111–1124 (2010). 
85. Zhu, J. et al. Relationships between transforming growth factor-beta1, myostatin, and 
decorin: implications for skeletal muscle fibrosis. J. Biol. Chem. 282, 25852 (2007). 
86. Yang, X., Yang, S., Wang, C. & Kuang, S. The hypoxia-inducible factors HIF1α and 
HIF2α are dispensable for embryonic muscle development but essential for postnatal 
muscle regeneration. J. Biol. Chem. 292, 5981–5991 (2017). 
87. Ono, Y., Sensui, H., Sakamoto, Y. & Nagatomi, R. Knockdown of hypoxia-inducible 
factor-1α by siRNA inhibits C2C12 myoblast differentiation. J. Cell. Biochem. 98, 642–
649 (2006). 
88. Majmundar, A. J. et al. HIF modulation of Wnt signaling regulates skeletal myogenesis in 
vivo. Development 142, 2405–2412 (2015). 
89. Villalta, S. A., Nguyen, H. X., Deng, B., Gotoh, T. & Tidball, J. G. Shifts in macrophage 
phenotypes and macrophage competition for arginine metabolism affect the severity of 
muscle pathology in muscular dystrophy . Human Molecular Genetics  18, 482–496 
90. Wynn, T. A. & Vannella, K. M. Macrophages in Tissue Repair, Regeneration, and 
Fibrosis. Immunity 44, 450–462 (2016). 
91. Farini, A. et al. T and B lymphocyte depletion has a marked effect on the fibrosis of 
dystrophic skeletal muscles in the scid/mdx mouse. J. Pathol. 213, 229 (2007). 
92. Chapman, M. A., Mukund, K., Subramaniam, S., Brenner, D. & Lieber, R. L. Three 
distinct cell populations express extracellular matrix proteins and increase in number 
during skeletal muscle fibrosis. Am. J. Physiol. Physiol. 312, C131–C143 (2017). 
93. Joe, A. W. B. et al. Muscle injury activates resident fibro/adipogenic progenitors that 
facilitate myogenesis. Nat. Cell Biol. 12, 153–163 (2010). 
100 
 
 
 
94. Heredia, J. E. et al. Type 2 Innate Signals Stimulate Fibro/Adipogenic Progenitors to 
Facilitate Muscle Regeneration. Cell 153, 376–388 (2013). 
95. Contreras, O., Rebolledo, D. L., Oyarzún, J. E., Olguín, H. C. & Brandan, E. Connective 
tissue cells expressing fibro/adipogenic progenitor markers increase under chronic 
damage: relevance in fibroblast-myofibroblast differentiation and skeletal muscle fibrosis. 
Cell Tissue Res. 364, 647–660 (2016). 
96. Lemos, D. R. et al. Nilotinib reduces muscle fibrosis in chronic muscle injury by 
promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat. Med. 21, 786–
794 (2015). 
97. Micallef, L. et al. The myofibroblast, multiple origins for major roles in normal and 
pathological tissue repair. Fibrogenesis & tissue repair 5, S5–S5 (2012). 
98. Mack, M. & Yanagita, M. Origin of myofibroblasts and cellular events triggering fibrosis. 
Kidney International 87, 297–307 (2015). 
99. Buehler, M. J. Nature Designs Tough Collagen: Explaining the Nanostructure of Collagen 
Fibrils. Proc. Natl. Acad. Sci. U. S. A. 103, 12285–12290 (2006). 
100. Smith, L. R., Hammers, D. W., Sweeney, H. L. & Barton, E. R. Increased collagen cross-
linking is a signature of dystrophin-deficient muscle: Collagen X-Linking in DMD. 
Muscle and Nerve 54, 71–78 (2016). 
101. Fadic, R. et al. Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of 
fibroblasts as cell source of these proteoglycans in the disease. J. Cell. Mol. Med. 10, 758–
769 (2006). 
102. Cynthia Martin, F. et al. Fibronectin is a serum biomarker for Duchenne muscular 
dystrophy. PROTEOMICS – Clin. Appl. 8, 269–278 (2014). 
103. Chen, X. & Li, Y. Role of matrix metalloproteinases in skeletal muscle: Migration, 
differentiation, regeneration and fibrosis. Cell Adh. Migr. 3, 337–341 (2009). 
104. Li, H., Mittal, A., Makonchuk, D. Y., Bhatnagar, S. & Kumar, A. Matrix 
metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle 
regeneration in muscular dystrophy. Hum. Mol. Genet. 18, 2584–2598 (2009). 
105. Blakney, A. K., Swartzlander, M. D. & Bryant, S. J. The effects of substrate stiffness on 
the in vitro activation of macrophages and in vivo host response to poly(ethylene glycol)-
based hydrogels. J. Biomed. Mater. Res. 100, 1375 (2012). 
106. Friedemann, M. et al. Instructing Human Macrophage Polarization by Stiffness and 
Glycosaminoglycan Functionalization in 3D Collagen Networks. Adv. Healthc. Mater. 6, 
1600967-n/a (2017). 
107. Engler, A. J. et al. Myotubes Differentiate Optimally on Substrates with Tissue-Like 
Stiffness: Pathological Implications for Soft or Stiff Microenvironments. J. Cell Biol. 166, 
877–887 (2004). 
108. Patel, K. & Shackel, N. A. Current status of fibrosis markers. Curr. Opin. Gastroenterol. 
30, 253–259 (2014). 
109. Joyce DO, N. C., Oskarsson MD, B. & Jin MD, PhD, L.-W. Muscle Biopsy Evaluation in 
Neuromuscular Disorders. Phys. Med. Rehabil. Clin. N. Am. 23, 609–631 (2012). 
110. Muntoni, F. Is a muscle biopsy in Duchenne dystrophy really necessary? Neurology 57, 
574–575 (2001). 
111. Olsen, D. B., Gideon, P., Jeppesen, T. D. & Vissing, J. Leg muscle involvement in 
facioscapulohumeral muscular dystrophy assessed by MRI. J. Neurol. 253, 1437–1441 
(2006). 
101 
 
 
 
112. Weber, M.-A., Nagel, A. M., Jurkat-Rott, K. & Lehmann-Horn, F. Sodium (23Na) MRI 
detects elevated muscular sodium concentration in Duchenne muscular dystrophy. 
Neurology 77, 2017–2024 (2011). 
113. Vappou, J. Magnetic resonance- and ultrasound imaging-based elasticity imaging 
methods: a review. Crit. Rev. Biomed. Eng. 40, 121–134 (2012). 
114. Jaffrin, M. Y. & Morel, H. Body fluid volumes measurements by impedance: A review of 
bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) methods. Med. Eng. 
Phys. 30, 1257–1269 (2008). 
115. Kim, C. T., Findley, T. W. & Reisman, S. R. Bioelectrical impedance changes in regional 
extracellular fluid alterations. Electromyogr. Clin. Neurophysiol. 37, 297 (1997). 
116. Ditroilo, M., Hunter, A. M., Haslam, S. & De Vito, G. The effectiveness of two novel 
techniques in establishing the mechanical and contractile responses of biceps femoris. 
Physiol. Meas. 32, 1315–1326 (2011). 
117. Moroni, G. et al. The value of 18F-FDG PET/CT in the assessment of active idiopathic 
retroperitoneal fibrosis. Eur. J. Nucl. Med. Mol. Imaging 39, 1635–1642 (2012). 
118. Guiraud, S. et al. Identification of serum protein biomarkers for utrophin based DMD 
therapy. Sci. Rep. 7, 43697 (2017). 
119. Nadarajah, V. D. et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for 
monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. 
Disord. 21, 569–578 (2011). 
120. Ayoglu, B. et al. Affinity proteomics within rare diseases: a BIO‐NMD study for blood 
biomarkers of muscular dystrophies. EMBO Molecular Medicine 6, 918–936 (2014). 
121. Rodino-Klapac, L. R., Chicoine, L. G., Kaspar, B. K. & Mendell, J. R. Gene therapy for 
Duchenne muscular dystrophy: Expectations and challenges. Arch. Neurol. 64, 1236–1241 
(2007). 
122. Zhang, Y. & Duan, D. Novel Mini–Dystrophin gene dual adeno-associated virus vectors 
restore neuronal nitric oxide synthase expression at the sarcolemma. Hum. Gene Ther. 23, 
98–103 (2012). 
123. Duan, D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular 
Dystrophy. Mol. Ther. 26, 2337–2356 (2018). 
124. Mendell, J. R. & Rodino-Klapac, L. R. Duchenne muscular dystrophy CRISPR/Cas9 
treatment. Cell Res. 26, 513–514 (2016). 
125. Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a 
mouse model of muscular dystrophy. Science 351, 400–403 (2016). 
126. Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of 
Duchenne muscular dystrophy. Science 351, 403–407 (2016). 
127. Aartsma-Rus, A. et al. Development of Exon Skipping Therapies for Duchenne Muscular 
Dystrophy: A Critical Review and a Perspective on the Outstanding Issues. Nucleic Acid 
Ther. 27, 251 (2017). 
128. Wilschut, K. J., Ling, V. B. & Bernstein, H. S. Concise Review: Stem Cell Therapy for 
Muscular Dystrophies. Stem Cells Transl. Med. 1, 833–842 (2012). 
129. Boldrin, L., Neal, A., Zammit, P. S., Muntoni, F. & Morgan, J. E. Donor satellite cell 
engraftment is significantly augmented when the host niche is preserved and endogenous 
satellite cells are incapacitated. Stem Cells 30, 1971 (2012). 
130. Kapsa, R. et al. In vivo and in vitro correction of the mdx dystrophin gene nonsense 
mutation by short-fragment homologous replacement. Hum. Gene Ther. 12, 629–642 
102 
 
 
 
(2001). 
131. Cossu, G. & Mavilio, F. Myogenic stem cells for the therapy of primary myopathies: 
Wishful thinking or therapeutic perspective? J. Clin. Invest. 105, 1669–1674 (2000). 
132. Bertoni, C. & Rando, T. A. Dystrophin gene repair in mdx muscle precursor cells in vitro 
and in vivo mediated by RNA-DNA chimeric oligonucleotides. Human gene therapy 13, 
707–718 (2002). 
133. Wong, S. H. A. et al. Evaluation of Sca-1 and c-Kit as selective markers for muscle 
remodelling by nonhemopoietic bone marrow cells. Stem cells 25, 1364–1374 (2007). 
134. Morales, M. G. et al. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and 
improves cell therapy. Human Molecular Genetics 22, 4938–4951 (2013). 
135. De Luca, A. Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an 
overview. Acta Myol. 31, 40 (2012). 
136. Simões e Silva, A. C., Silveira, K. D., Ferreira, A. J. & Teixeira, M. M. ACE2, 
angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 
169, 477–492 (2013). 
137. Israili, Z. H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in 
hypertension. J. Hum. Hypertens. 14, S73–S86 (2000). 
138. Tyralla, K. et al. High-dose enalapril treatment reverses myocardial fibrosis in 
experimental uremic cardiomyopathy. PLoS One 6, e15287 (2011). 
139. Brilla, C. G., Funck, R. C. & Rupp, H. Lisinopril-mediated regression of myocardial 
fibrosis in patients with hypertensive heart disease. Circulation 102, 1388–1393 (2000). 
140. Adamo, C. M. et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of 
Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 107, 19079–19083 (2010). 
141. Buyse, G. M. et al. Efficacy of idebenone on respiratory function in patients with 
Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind 
randomised placebo-controlled phase 3 trial. Lancet 385, 1748–1757 (2015). 
142. Hori, Y. S. et al. Resveratrol ameliorates muscular pathology in the dystrophic mdx 
mouse, a model for Duchenne muscular dystrophy. J. Pharmacol. Exp. Ther. 338, 784–
794 (2011). 
143. Lehmann-Horn, F. et al. Rationale for treating oedema in Duchenne muscular dystrophy 
with eplerenone. Acta Myol. 31, 31 (2012). 
144. Hastie, N. D. Wilms’ tumour 1 (WT1) in development, homeostasis and disease. 
Development 144, 2862–2872 (2017). 
145. Thibaud, E. et al. Donor splice-site mutations in WT1 are responsible for Frasier 
syndrome. Nat. Genet. 17, 467–470 (1997). 
146. Pelletier, J. et al. Germline mutations in the Wilms’ tumor suppressor gene are associated 
with abnormal urogenital development in Denys-Drash syndrome. Cell 67, 437–447 
(1991). 
147. Scharnhorst, V., Van der Eb, A. J. & Jochemsen, A. G. WT1 proteins: Functions in 
growth and differentiation. Gene 273, 141–161 (2001). 
148. Wagner, K., Wagner, N. & Schedl, A. The complex life of WT1. J. Cell Sci. 116, 1653–
1658 (2003). 
149. Sharma, P. M., Bowman, M., Madden, S. L., Rauscher, F. J. & Sukumar, S. RNA editing 
in the Wilms’ tumor susceptibility gene, WT1. Genes Dev. 8, 720–731 (1994). 
150. Moore, A. W., McInnes, L., Kreidberg, J., Hastie, N. D. & Schedl, A. YAC 
complementation shows a requirement for Wt1 in the development of epicardium, adrenal 
103 
 
 
 
gland and throughout nephrogenesis. Development 126, 1845 (1999). 
151. Herzer, U., Crocoll, A., Barton, D., Howells, N. & Englert, C. The Wilms tumor 
suppressor gene wt1 is required for development of the spleen. Curr. Biol. 9, 837,S1-
840,S1 (1999). 
152. Kreidberg, J. A. et al. WT-1 is required for early kidney development. Cell 74, 679–691 
(1993). 
153. Miyamoto, Y., Taniguchi, H., Hamel, F., Silversides, D. W. & Viger, R. S. A 
GATA4/WT1 cooperation regulates transcription of genes required for mammalian sex 
determination and differentiation. BMC Mol. Biol. 9, 44 (2008). 
154. Wilhelm, D. & Englert, C. The Wilms tumor suppressor WT1 regulates early gonad 
development by activation of Sf1. Genes Dev. 16, 1839–1851 (2002). 
155. Motamedi, F. J. et al. WT1 controls antagonistic FGF and BMP-pSMAD pathways in 
early renal progenitors. Nat. Commun. 5, 4444 (2014). 
156. Hartwig, S. et al. Genomic characterization of Wilms’ tumor suppressor 1 targets in 
nephron progenitor cells during kidney development. Development 137, 1189–1203 
(2010). 
157. Martinez-Estrada, O. M. et al. Wt1 is required for cardiovascular progenitor cell formation 
through transcriptional control of snail and E-cadherin. Nat. Genet. 42, 89–93 (2010). 
158. Cano, E., Carmona, R. & Muñoz-Chápuli, R. Wt1-expressing progenitors contribute to 
multiple tissues in the developing lung. Am. J. Physiol. Cell. Mol. Physiol. 305, L322–
L332 (2013). 
159. Chau, Y.-Y. et al. Acute multiple organ failure in adult mice deleted for the 
developmental regulator Wt1. PLoS Genet. 7, e1002404 (2011). 
160. Bandiera, R. et al. WT1 Maintains Adrenal-Gonadal Primordium Identity and Marks a 
Population of AGP-like Progenitors within the Adrenal Gland. Dev. Cell 27, 5–18 (2013). 
161. Palmer, R. E. et al. WT1 regulates the expression of the major glomerular podocyte 
membrane protein podocalyxin. Curr. Biol. 11, 1805–1809 (2001). 
162. Wagner, N., Wagner, K.-D., Xing, Y., Scholz, H. & Schedl, A. The major podocyte 
protein nephrin is transcriptionally activated by the Wilms’ tumor suppressor WT1. J. Am. 
Soc. Nephrol. 15, 3044–3051 (2004). 
163. Smart, N. et al. De novo cardiomyocytes from within the activated adult heart after injury. 
Nature 474, 640–644 (2011). 
164. Wagner, K.-D. et al. Oxygen-regulated expression of the Wilms’ tumor suppressor Wt1 
involves hypoxia-inducible factor-1 (HIF-1). FASEB Journal 17, 1364–1366 (2003). 
165. Caricasole, A. et al. RNA Binding by the Wilms Tumor Suppressor Zinc Finger Proteins. 
Proc. Natl. Acad. Sci. U. S. A. 93, 7562–7566 (1996). 
166. Richard, D. J., Schumacher, V., Royer-Pokora, B. & Roberts, S. G. E. Par4 is a 
coactivator for a splice isoform-specific transcriptional activation domain in WT1. Genes 
Dev. 15, 328–339 (2001). 
167. Silberstein, G. B., Horn, K. Van, Strickland, P., Roberts, C. T. & Daniel, C. W. Altered 
Expression of the WT1 Wilms Tumor Suppressor Gene in Human Breast Cancer. Proc. 
Natl. Acad. Sci. U. S. A. 94, 8132–8137 (1997). 
168. Natoli, T. A. et al. A mutant form of the wilms’ tumor suppressor gene WT1 observed in 
denys-drash syndrome interferes with glomerular capillary development. J. Am. Soc. 
Nephrol. 13, 2058–2067 (2002). 
169. Davies, R. C. et al. WT1 interacts with the splicing factor U2AF65 in an isoform-
104 
 
 
 
dependent manner and can be incorporated into spliceosomes. Genes Dev. 12, 3217–3225 
(1998). 
170. Maheswaran, S., Englert, C., Bennett, P., Heinrich, G. & Haber, D. A. The WT1 gene 
product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 9, 2143–2156 
(1995). 
171. Maheswaran, S. et al. Physical and Functional Interaction Between WT1 and p53 Proteins 
. Proceedings of the National Academy of Sciences of the United States of America  90, 
5100–5104 (1993). 
172. Rupprecht, H. D., Drummond, I. A., Madden, S. L., Rauscher, F. J. & Sukhatme, V. P. 
The wilms’ tumor suppressor gene WT1 is negatively autoregulated. J. Biol. Chem. 269, 
6198 (1994). 
173. Drummond, L. et al. Repression of the Insulin-Like Growth Factor II Gene by the Wilms 
Tumor Suppressor WT1. Science (80-. ). 257, 674–678 (1992). 
174. Duarte, A., Caricasole, A., Graham, C. F. & Ward, A. Wilms’ tumour-suppressor protein 
isoforms have opposite effects on Igf2 expression in primary embryonic cells, 
independently of p53 genotype. Br. J. Cancer 77, 253–259 (1998). 
175. Ryan, G., Steele-Perkins, V., Morris, J. F., Rauscher, F. J. & Dressler, G. R. Repression of 
Pax-2 by WT1 during normal kidney development. Development 121, 867–75 (1995). 
176. Wang, Z. Y., Madden, S. L., Deuel, T. F. & F J Rauscher, 3rd. The Wilms’ tumor gene 
product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. 
Journal of Biological Chemistry 267, 21999 (1992). 
177. Parenti, R. et al. Immunohistochemical expression of wilms’ tumor protein (WT1) in 
developing human epithelial and mesenchymal tissues. Acta Histochem. 115, 70–75 
(2013). 
178. Niksic, M., Slight, J., Sanford, J. R., Caceres, J. F. & Hastie, N. D. The Wilms’ tumour 
protein (WT1) shuttles between nucleus and cytoplasm and is present in functional 
polysomes . Human molecular genetics  13, 463–471 
179. Sontake, V. et al. Fibrocytes Regulate Wilms Tumor 1-Positive Cell Accumulation in 
Severe Fibrotic Lung Disease. J. Immunol. 195, 3978–3991 (2015). 
180. Sontake, V. et al. Wilms’ tumor 1 drives fibroproliferation and myofibroblast 
transformation in severe fibrotic lung disease. JCI Insight 3, (2018). 
181. Karki, S. et al. Wilms’ tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and 
transition into myofibroblasts in idiopathic pulmonary fibrosis. FASEB J. 28, 1122–1131 
(2014). 
182. Crawford, J., Raykha, C., Charles, D., Gan, B. & O’Gorman, D. WT1 expression is 
increased in primary fibroblasts derived from Dupuytren’s disease tissues. J. Cell 
Commun. Signal. 9, 347–352 (2015). 
183. McGreevy, J. W., Hakim, C. H., McIntosh, M. A. & Duan, D. Animal models of 
Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis. Model. 
Mech. 8, 195–213 (2015). 
184. Sicinski, P. et al. The Molecular Basis of Muscular Dystrophy in the mdx Mouse: A Point 
Mutation . Science  244, 1578–1580 (1989). 
185. Bulfield, G., Siller, W. G., Wight, P. A. L. & Moore, K. J. X chromosome-linked 
muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. U. S. A. 81, 1189–1192 
(1984). 
186. Zhou, L. et al. Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation 
105 
 
 
 
and fibrosis in mdx mice. J. Neurol. Sci. 264, 106–111 (2007). 
187. Huang, P. et al. Impaired Respiratory Function in mdx and mdx/utrn+/- Mice. Muscle and 
Nerve 43, 263–267 (2011). 
188. Grady, R. M. et al. Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and 
Dystrophin: A Model for Duchenne Muscular Dystrophy. Cell 90, 729–738 (1997). 
189. McDonald, A. A., Hebert, S. L., Kunz, M. D., Ralles, S. J. & McLoon, L. K. Disease 
course in mdx:utrophin+/− mice: comparison of three mouse models of Duchenne 
muscular dystrophy. Physiol. Rep. 3, e12391 (2015). 
190. Quinlan, J. G. et al. Evolution of the mdx mouse cardiomyopathy: Physiological and 
morphological findings. Neuromuscul. Disord. 14, 491–496 (2004). 
191. Matsumura, K. & Campbell, K. P. Dystrophin-glycoprotein complex: Its role in the 
molecular pathogenesis of muscular dystrophies. Muscle Nerve 17, 2–15 (1994). 
192. Fisher, R. et al. Amelioration of the dystrophic phenotype of mdx mice using a truncated 
utrophin transgene. Nature 384, 349–353 (1996). 
193. Campbell, K. P., Ervasti, J. M., Ohlendieck, K., Matsumura, K. & Kahl, S. D. Association 
of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. 
Nature 360, 588–591 (1992). 
194. Gutpell, K. M., Hrinivich, W. T. & Hoffman, L. M. Skeletal muscle fibrosis in the 
mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular 
dystrophy. PLoS One 10, (2015). 
195. van Putten, M. et al. Comparison of skeletal muscle pathology and motor function of 
dystrophin and utrophin deficient mouse strains. Neuromuscular Disorders 22, 406–417 
196. Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. 
Methods 9, 676–682 (2012). 
197. Rueden, C. T. et al. ImageJ2: ImageJ for the next generation of scientific image data. 
BMC Bioinformatics 18, 529–26 (2017). 
198. Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. 
Sci. Rep. 7, 16878–7 (2017). 
199. Kramarzova, K. et al. Real-time PCR quantification of major wilms’ tumor gene 1 (WT1) 
isoforms in acute myeloid leukemia, their characteristic expression patterns and possible 
functional consequences. Leukemia 26, 2086–2095 (2012). 
200. Magro, G. et al. Oncofetal expression of wilms’ tumor 1 (WT1) protein in human fetal, 
adult and neoplastic skeletal muscle tissues. Acta Histochem. 117, 492–504 (2015). 
201. Ramani, P. & Cowell, J. K. The expression pattern of Wilms’ tumour gene (WT1) product 
in normal tissues and paediatric renal tumours. J. Pathol. 179, 162–168 (1996). 
202. Murphy, A. P. et al. Noninvasive quantification of fibrosis in skeletal and cardiac muscle 
in mdx mice using EP3533 enhanced magnetic resonance imaging. Magn. Reson. Med. 
(2018). 
203. Verhaart, I. E. C. et al. Assessment of cardiac function in three mouse dystrophinopathies 
by magnetic resonance imaging. Neuromuscular Disorders 22, 418–426 (2011). 
204. Bondoc, A. B. et al. Application of 3-D echocardiography and gated micro-computed 
tomography to assess cardiomyopathy in a mouse model of Duchenne muscular 
dystrophy. Ultrasound Med. Biol. 40, 2857–2867 (2014). 
205. Wagner, K.-D. et al. The Wilms’ tumor suppressor Wt1 is expressed in the coronary 
vasculature after myocardial infarction. FASEB J. 16, 1117–1119 (2002). 
206. Yang, W. & Hu, P. Skeletal muscle regeneration is modulated by inflammation. Journal 
106 
 
 
 
of Orthopaedic Translation 13, 25–32 (2018). 
207. Marcet-Palacios, M., Davoine, F., Adamko, D. J., Moqbel, R. & Befus, A. D. Human 
lymphocytes express the transcriptional regulator, Wilms tumor 1: The role of WT1 in 
mediating nitric oxide-dependent repression of lymphocyte proliferation. Biochemical and 
Biophysical Research Communications 363, 283–287 (2007). 
208. Scharnhorst, V., Dekker, P., Eb, A. J. van der & Jochemsen, A. G. Internal Translation 
Initiation Generates Novel WT1 Protein Isoforms with Distinct Biological Properties. J. 
Biol. Chem. 274, 23456–23462 (1999). 
209. Dohi, S. et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one 
year: A case report. Anticancer Res. 31, 2441–2446 (2011). 
210. Dubrovsky, L. et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor 
resistance in human BCR-ABL(+) leukemias. Blood 123, 3296–3304 (2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
 
 
APPENDICIES 
 
Appendix A: Approval of Animal Protocol 
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Appendix B: Representative images of negative control muscle in 4-5 week old wildtype, 
Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice. 
 
Gastrocnemius, diaphragm, and heart muscle was acquired from 4-5 week old mice of several 
genotypes, and immunohistochemically stained without an antibody. Representative images of 
IHC analysis of muscle are shown for wildtype (A-C), Mdx (D-F), Mdx/Utrn+/- (G-I), and 
Mdx/Utrn-/- (J-L) mice. In the bottom left corner, a section of magnified nuclei are provided for 
examination. Asterisks indicate large example regions of cells resembling inflammatory infiltrate 
(scale bar = 100μm). 
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Appendix C: Representative images of negative control muscle in 8-10 week old wildtype, 
Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice. 
 
Gastrocnemius, diaphragm, and heart muscle was acquired from 8-10 week old mice of several 
genotypes, and immunohistochemically stained without an antibody. Representative images of 
IHC analysis of muscle are shown for wildtype (A-C), Mdx (D-F), Mdx/Utrn+/- (G-I), and 
Mdx/Utrn-/- (J-L) mice. In the bottom left corner, a section of magnified nuclei are provided for 
examination. Asterisks indicate large example regions of cells resembling inflammatory infiltrate 
(scale bar = 100μm). 
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Appendix D: Representative images of negative control muscle in 10-14 month old 
wildtype, Mdx, and Mdx/Utrn+/- mice. 
 
Gastrocnemius, diaphragm, and heart muscle was acquired from 10-14 month old mice of 
several genotypes, and immunohistochemically stained without an antibody. Representative 
images of IHC analysis of muscle are shown for wildtype (A-C), Mdx (D-F), and Mdx/Utrn+/- 
(G-I) mice. In the bottom left corner, a section of magnified nuclei are provided for examination. 
Asterisks indicate large example regions of cells resembling inflammatory infiltrate (scale bar = 
100μm). 
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Appendix E: Example division of image into muscle cytoplasm and non-muscle tissue 
components. 
 
An example section of 10-14 month old Mdx/Utrn+/- gastrocnemius evaluated 
immunohistochemically for Wt1, with nuclei counterstained using hematoxylin. The region of 
muscle cytoplasm has been identified with red coloring, while the region of non-muscle tissue 
has been identified with teal coloring. In the case where the border of the image is present, a 
prominent edge is present between tissue structures, or where there is uncertainty over whether 
the region is muscle or non-muscle tissue, no coloring has been conducted (scale bar = 100μm).  
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Appendix F: Representative images of immunohistochemically stained, hematoxylin 
negative, muscle in 4-5 week old wildtype, Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice. 
 
Gastrocnemius, diaphragm, and heart muscle was acquired from 4-5 week old mice of several 
genotypes, and immunohistochemically stained for Wt1, in the absence of hematoxylin. 
Representative images of Wt1 IHC analysis of muscle are shown for wildtype (A-C), Mdx (D-F), 
Mdx/Utrn+/- (G-I), and Mdx/Utrn-/- (J-L) mice. In the bottom left corner, a section of magnified 
nuclei are provided for examination. Asterisks indicate large example regions of cells resembling 
inflammatory infiltrate (scale bar = 100μm). 
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Appendix G: Representative images of immunohistochemically stained, hematoxylin 
negative, muscle in 8-10 week old wildtype, Mdx, Mdx/Utrn+/-, and Mdx/Utrn-/- mice. 
 
Gastrocnemius, diaphragm, and heart muscle was acquired from 8-10 week old mice of several 
genotypes, and immunohistochemically stained for Wt1, in the absence of hematoxylin. 
Representative images of Wt1 IHC analysis of muscle are shown for wildtype (A-C), Mdx (D-F), 
Mdx/Utrn+/- (G-I), and Mdx/Utrn-/- (J-L) mice. In the bottom left corner, a section of magnified 
nuclei are provided for examination. Asterisks indicate large example regions of cells resembling 
inflammatory infiltrate (scale bar = 100μm). 
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Appendix H: Representative images of immunohistochemically stained, hematoxylin 
negative, muscle in 10-14 month old wildtype, Mdx, and Mdx/Utrn+/- mice. 
 
Gastrocnemius, diaphragm, and heart muscle was acquired from 10-14 month old mice of 
several genotypes, and immunohistochemically stained for Wt1, in the absence of hematoxylin. 
Representative images of Wt1 IHC analysis of muscle are shown for wildtype (A-C), Mdx (D-F), 
and Mdx/Utrn+/- (G-I) mice. In the bottom left corner, a section of magnified nuclei are 
provided for examination. Asterisks indicate large example regions of cells resembling 
inflammatory infiltrate (scale bar = 100μm). 
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 Appendix I: Primer efficiency validation for total Wt1 and Wt1 isoform controls. 
 
Graphs depicting primer validation for qPCR experiments, where the absolute value of the slope 
of the graph is ≤0.1. For whole Wt1, validation was conducted against the geometric mean of 
Gapdh, Actb, and Ppia (A). For each major Wt1 isoform, A (B), B (C), C (D), and D (E) 
validation was conducted against the sum of all isoforms together.  
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Appendix J: Two-Way ANOVA with Tukey's Multiple Comparisons Tests for all groups 
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P-values for two-way ANOVA on gastrocnemius (A), diaphragm (B), and heart (C), with 
Tukey’s multiple comparisons test, conducted for collagen content, proportion of Wt1 
immunoreactive nuclei, muscle cytoplasm immunoreactivity, and non-muscle immunoreactivity, 
for age point. Asterisks indicate significant differences between groups (* < 0.050, ** < 0.010, 
*** < 0.001). Three biological and three technical replicates were used.  
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Appendix K: Wt1 immunoreactivity does not change in muscle cytoplasm or non-muscle 
tissue compared to the age-matched wildtype. 
 
Graphs depicting Wt1 immunoreactivity as a fraction of the muscle cytoplasm, for the 
gastrocnemius (A), diaphragm (C), and heart (E), or as a fraction of the non-muscle tissue, for 
the gastrocnemius (D), diaphragm (E), and heart (F). Percent of positive tissue area is expressed 
as mean +SD. Asterisks indicate significant differences with age-matched wildtype (* < 0.050, 
** < 0.010, *** < 0.001). Three biological and three technical replicates were used. 
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Appendix L: Wt1 immunoreactivity does not change in muscle cytoplasm or non-muscle 
tissue over time.  
 
Graphs depicting Wt1 immunoreactivity as a fraction of the muscle cytoplasm, for the 
gastrocnemius (A), diaphragm (C), and heart (E), or as a fraction of the non-muscle tissue, for 
the gastrocnemius (D), diaphragm (E), and heart (F). Percent of positive tissue area is expressed 
as mean +SD. Asterisks indicate significant differences with age-matched wildtype (* < 0.050, 
** < 0.010, *** < 0.001). Three biological and three technical replicates were used. 
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Appendix M: There is significantly greater collagen deposition in 8-10 week old diaphragm 
compared to 8-10 week old heart. 
 
Graphs depicting Wt1 immunoreactivity as a fraction of nuclei positive (A), area of the muscle 
cytoplasm positive (C), and area of the non-muscle tissue positive (D), as well as the collagen 
content of the tissue (B), for 8-10 week old wildtype mouse diaphragm, gastrocnemius, and 
heart. Percent of positive nuclei or tissue area is expressed as mean +SD. Asterisks indicate 
significant differences. (* < 0.050, ** < 0.010, *** < 0.001). Three biological and three technical 
replicates were used. 
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